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ABSTRACT OF THE DISSERTATION
Gene Association Mapping
in the Era of Next-Generation Sequencing and Systems Biology
by
Tianxiao Zhang
Doctor of Philosophy in Biology and Biomedical Sciences
Human and Statistical Genetics
Washington University in St. Louis, 2016
Professor John P. Rice, Chair
In the past decade, advancement of genotyping technology, first microarray then
―next-generation‖ sequencing, has enabled scientists to examine the susceptible genes that
contribute to the risk of complex disorders using a genome-wide, ―hypothesis free‖ strategy.
However, despite this ―hypothesis free‖ label, these genome-wide approaches (including
genome-wide association and whole genome sequencing studies) depend on two implicit
assumptions. The first assumption is that the genetic risk of complex traits is contributed by
independent genes/variants (assumption of independence).The second assumption is that
different genes have equal potentiality to confer to the genetic predisposition of the complex
traits (assumption of equality). Despite the huge success in susceptible gene association mapping
in the last decade, more and more evidence has indicated that these two underlying assumptions
of these genome-wide approaches may not be sound. Other than just studying one locus at a time,
alternative methods which can carry out global analyses of biological molecules in populations

xi

have been developed to understand the influence of the whole biological system on complex
traits. Network based approaches, in particular, have proven informative.
This dissertation will cover a few important issues concerning sequencing based study design
and its applications in chapter II, III and IV. Human protein-protein interaction network will be
constructed and a few of human gene network related issues will be studied and discussed in
chapter V and VI. Abstracts for each chapter were summarized as followed.
Chapter 2: In this chapter, we proposed a two-stage, gene-based method for association mapping
of rare variants by applying four different non-collapsing algorithms. Using the Genome
Analysis Workshop 18 whole genome sequencing dataset of simulated blood pressure
phenotypes, we studied and contrasted the false positive rate of each algorithm using receiver
operating characteristic curves. The statistical power of these methods was also evaluated and
compared through the analysis of 200 simulated replications in a smaller genotype data set. We
showed that the Fisher’s method was superior to the other three 3 non-collapsing methods, but
was no better than the standard method implemented with famSKAT.
Chapter 3: In this chapter, we aimed to identify potential susceptibility variants for bipolar
disorder via the combination of exome sequencing and linkage analysis on 6 related subjects
from a four-generation family. Our study identified a list of five potential candidate genes for
bipolar disorder. Among these five genes, GRID1 (Glutamate Receptor Delta-1 Subunit), which
was previously reported to be associated with several psychiatric disorders and brain related
traits, is of particular interest. Our findings suggest a potential role for these genes and the related
rare variants in the onset and development of bipolar disorder in this one family.
Chapter 4: In this chapter, we investigated the potential of FMO genes to confer risk of nicotine
dependence via deep targeted sequencing in 2,820 study subjects comprising of nicotine 1,583
xii

dependents and 1,237 controls from European and African Americans. Specifically, we focused
on the two genomic segments including FMO1, FMO3 and the pseudo gene FMO6P, and aimed
to investigate the potential association between FMO genes and nicotine dependence. We
identified different clusters of significant common variants in European (with most significant
SNP rs6674596, P=0.0004, OR=0.67, MAF_EA=0.14) and African Americans (with the most
significant SNP rs6608453, P=0.001, OR=0.64, MAF_AA=0.1). Most of the significant variants
identified were SNPs located within intronic regions or with unknown functional significance.
Chapter 5: In this chapter, we aimed to investigate the followed three scientific questions: 1) Can
centrality reflect the biological significance of genes in a general human gene network? 2)
Among these four commonly used centrality measures, does any of them outperform others? 3)
Will they do better if we combine several centrality measures together using machine learning
algorithms? To answer these scientific questions, we constructed a comprehensive human
gene-gene network using protein-protein interaction data. Four essential gene sets were extracted
from a variety of data sources serving as true answers in the evaluation and optimization process.
Our analytic results indicated that there is a connection between the essentiality and centrality of
human genes. A pattern of strong correlations was identified among the four commonly used
centrality measures for a general human PPI network and the performance of each centrality
measure was similar to others serving as predictors of the essentiality of genes. The improvement
of the prediction models was limited when we combined several different centrality measures.
Chapter 6: In this chapter, we aimed to investigate the potential enrichment pattern in centrality
of susceptible genes for certain complex disorders in a functional specific sub-network. Gene
expression data of human brain tissue recorded in the Human Protein Atlas were extracted and
utilized to construct a series of brain function specific sub-networks. Susceptible genes from
xiii

three categories of complex disorders, including neurodegenerative disorder, psychiatric disorder
and non-brain related disorder, were extracted from the GWAS catalogue. We identified a
significant enrichment pattern of high centrality of susceptibility genes contributing to
neurodegenerative and psychiatric disorders in these sub-networks. Our findings indicate that
susceptibility genes of complex disorder might have higher centralities in functional specific
sub-networks.

xiv

Chapter 0: Prologue

―On proceeding to the spot, I found that nearly all the deaths had taken place
within a short distance of the pump. There were only ten deaths in houses situated
decidedly nearer to another street-pump. In five of these cases the families of the
deceased persons informed me that they always sent to the pump in Broad Street, as they
preferred the water to that of the pumps which were nearer. In three other cases, the
deceased were children who went to school near the pump in Broad Street...‖
—John Snow, On the Mode of Communication of Cholera, 1855

―My experiments with single traits all lead to the same result: that from the seeds
of hybrids, plants are obtained half of which in turn carry the hybrid trait (Aa), the other
half, however, receive the parental traits A and a in equal amounts. Thus, on the average,
among four plants two have the hybrid trait Aa, one the parental trait A, and the other the
parental trait a. Therefore, 2Aa+A+a or A+2Aa+a is the empirical simple series for two
differing traits.‖
—Gregor Mendel, Letter to Carl Nägeli, 1866

―A LADY declares that by tasting a cup of tea made with milk she can
discriminate whether the milk or the tea infusion was first added to the cup. We will
consider this problem of designing an experiment by means of which this assertion can be
tested.‖
—Sir Ronald A. Fisher, The Design of Experiments, 1935

1

Chapter 1: Overview
1.1 Genetic Epidemiology : Its Origin, Definition, and Early
Development
1.1.1

What is genetic epidemiology?

Genetic epidemiology, as the name suggests, is an inter-discipline that is related to
both epidemiology and genetics. I would like to describe a genetic epidemiologist as an
epidemiologist who tries to unravel the enigma of (human) genetics using the tool sets of
statistics. In this sense, genetic epidemiology, as a field of study, can be traced back to
three origins. The first one is modern epidemiology. The core methodology and
terminology used in genetic epidemiology are directly borrowed from it. Another one is
genetics. Unraveling the genetic (and the environmental) determinants of human traits
and disorders are the major goals of genetic epidemiology. Last but not least, statistics.
Statistics is the fundamental tool utilized in genetic epidemiology study, and statistical
estimation is required in most, if not all, genetic epidemiology related publications. Just
as other thriving disciplines, genetic epidemiology is also an evolving study subject that
keeps on adapting to the progress of biomedical science in modern days. Besides the
three origins I mentioned above, genomics and bioinformatics are also involved in
genetic epidemiology studies in the 21th century.
From the perspective of epidemiology, there are mainly two kinds of study designs:
observational and experimental. In observational studies, researchers only observe their
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study subjects and do not intervene. While in experimental studies, a researcher, instead
of observing from the sidelines, controls the factors affecting a certain case study [1].
Genetic epidemiology, as a concept used in this thesis (and in most academic scenarios),
is strictly observational. This perspective actually provides us a chance to distinguish
genetic epidemiology and human genetics. Human genetics offers a wider concept
compared to genetic epidemiology. Besides observational studies (genetic epidemiology),
it also includes experimental studies performed using model organisms. Both study
designs have its advantage and disadvantage. Confounders (population stratification, e.g.),
especially those unknown, can always be problematic for observational studies (genetic
epidemiology). They place obstacles for the ―giant leap‖ from statistical association to
causal inference. On the other hand, experimental studies (based on model organisms)
could handle this confounding issue very well. However, generalization is a major weak
point of these kinds of studies when researchers try to trace the significance of some
causal variants identified in model organisms (mouse, e.g.) using gene
knockout/knockdown technology back to human beings.
Genetic epidemiology studies try to clarify the following logically ordered scientific
questions about human traits\disorders:
1) Does this trait/disorder have a pattern of familial aggregation (family clustering)?
2) Can shared genes explain the familial aggregation?
3) How much can these shared genes explain the familial aggregation?
4) Where are these genes and how do they contribute to the trait/disorder?

3

A first observation of genetic related traits/disorders is always their familial
clustering pattern. However, this pattern is not necessary due to shared genes but could
also be share environments. Several study designs, including immigration studies and
adoption studies, can provide a way to separate the genetic variance from the
environmental variance. After knowing the fact that genes matter, the next question is
that how much these genes could explain the familial clustering pattern. Twin studies are
a common study design to answer this question. Once we know the phenotypic variance
that could be explained by genetic variance, then where are these genes? Linkage studies
and gene association mapping could answer this question. Genetic data are not needed to
answer the first three questions. I will briefly discuss them in the next section.
1.1.2

Early genetic epidemiology studies: nature versus nurture

Before scientists took a great interest in it, family aggregation as an observation
from everyday life has long been noticed and characterized in some idioms, such as Like
father like son or A wise goose never lays a tame egg. The early genetic epidemiology
studies can be traced back to the work of Francis Galton, who was half-cousin of Charles
Darwin, in the 19th century. Galton was interested in answering the question whether
human traits were hereditary. He devoted most of his academic life to devise large-scale
data collection of different measurements of human traits, from mental characteristic to
intelligence. Galton proposed that if eminence was hereditary, there should be more
eminent men among the relatives than among the general population, and the numbers of
eminent relatives dropped off when going from first degree to second degree relatives,
and from second degree to third [2]. This is a typical familial aggregation study design,
although it is not enough to test whether a specific trait is hereditary because of the mixed
4

genetic and environmental variance. Galton recognized the limitations of his methods in
his works, and believed the question could be better studied by comparisons of twins. He
also proposed adoption studies.
An Adoption study investigates the similarity between the adoptees and their
biological and adoptive parents. The similarity between adoptees and their biological
parents is expected to be heritable, while similarity with their adoptive parents is shared
environmental effect. With this study design, an adoption study can separate the effects
of heredity and environment. However, it is difficult to link an adopted child to their
biological family. Therefore, a simplified version (familial design) is sometimes applied
by comparing the non-biological siblings who are reared in the same household.
Additionally, another study design, the so called ―immigration study‖ can do the same
thing by comparing the phenotype of immigrants, populations in their original countries
and populations in their resident country. The phenotypic similarity between immigrants
and populations of their original country can be explained by the shared genetic
background, while similarity with populations of their resident country can be explained
by the shared environments.
Both adoption and immigration studies could offer us a way to deduce whether
observed variation in a particular trait is due to environmental or to biological factors
(sometimes popularly expressed as the "nature versus nurture" debate). The next question
would then be how much of the variation in a human trait is due to variation in genetic
factors. The portion of phenotypic variance that can be explained by genetic factors is
summarized as the concept of heritability. Traditionally, heritability can be estimated
from empirical data and simple study designs, such as the correlation of offspring and
5

parental phenotypes, the correlation of full or half siblings, and the difference in the
correlation of monozygotic (MZ) and dizygotic (DZ) twin pairs. In the past decades, the
heritability of many human complex disorders/traits has been estimated and summarized
them in Table 1.1.
A major feature of these early epidemiology studies is that no genotypic data is
involved. Therefore it is impossible to map the susceptible/causal genes that contribute to
those human traits/disorders. This deficiency will only be remedied when there is a set of
genetic markers which cover the human genome and a cost effective experimental
technology to genotype them. The advancement of DNA technology in the 1980s and
1990s meet these two conditions and enables the genetic epidemiologist to conduct
research to finally locate the susceptible/causal genes in the human genome.

1.2 Gene Mapping: From Linkage study to Genome-wide Association
Study
1.2.1.

Linkage and candidate gene based association study

The goal of a linkage study is to identify the genetic linkage between genetic
markers and potential trait/disorder loci occurred during meiosis. The genetic linkage
segment can range from a couple to a dozen of megabases (Mb), and this build-in
mechanism determines that a linkage study can only identify a genetic locus that covers
several Mbs on a chromosome. Short tandem repeats (STR), which are genetic
polymorphisms that consist of a unit of 2 to 13 nucleotides repeated hundreds of times in
a row on the DNA strand, is an efficient genetic marker for conducting linkage study.
STRs are multi-allelic genetic markers, and that means they are much more informative
6

compared to single nucleotide polymorphisms (SNPs) of which most are biallelic.
Genotying of 400 STRs is enough for a typical genome-wide linkage scan while it may
take more than 3,000 SNPs to achieve the same statistical power. Compared to a linkage
study, an association study, which is based on linkage disequilibrium (LD), is more
accurate and can pinpoint the location of specific susceptible genes. Nevertheless, it was
too expensive to have a half million SNPs genotyped for one subject when conducting a
genome-wide association study (GWAS) in the 1990s. To make a compromise between
the experimental costs and accuracy in gene association mapping, a very popular
association mapping strategy back to the 1990s (and early 2000s) was to conduct a
genome-wide linkage scan first, and the significant loci identified in the linkage study,
which is a chromosomal region of around 10-20 cM, was scrutinized in a candidate gene
based association study based on a set of dozens of SNPs selected within the candidate
significant region (usually 10-20 genes). Although this study design is logically sound
and financially feasible, it is not a systematic solution to identify genes for human
complex disorders/traits. An insightful review published in 2012 estimated that the total
money spent on candidate gene based association studies and linkage studies in the 1990s
and the 2000s exceeded $250M, but had generated very limited findings compared to the
findings of GWAS in its first five years (2007-2011, ) which also spend around $250M
[3].
1.2.2

Genome-wide association study

Although the first GWAS results were published in 2005 and 2006, GAWS as a
theoretical design had been proposed by Risch and Merikangas ten years earlier. In their
1996 landmark paper, they showed that an association study performed with one million
7

variants genotyped in a set of unrelated subjects will be more powerful than the genome
linkage scan that was widely utilized in gene association mapping studies at that time [4].
The breakthrough in SNP genotyping using microarray technology [5] finally turned this
once theoretical design into a real one. The first published GWAS study was a study
conducted on age-related macular degeneration (ARMD) [6]. What may amaze
researchers today is that this study has successfully identified a significant locus (and it is
proved that this locus contribute largely on the risk of ARMD) with around 100,000
SNPs genotyped in only 96 cases and 50 controls [6]. After that, genome-wide
association studies (GWAS) have rapidly become a standard method for discovering
susceptible genes for a variety of complex disorders/traits, and it is widely believed to be
a promising tool for identifying potential susceptible loci. So far, many GWAS studies
are published annually. As of June, 2015, 2,414 GWA studies in total have been
published [7]. Around 10,000 susceptible loci have been reported to be significantly
associated with around 1,000 complex human traits/disorders [7]. Up to now, most of our
knowledge of susceptible genes that contribute to the human complex disorders/traits was
generated by GWAS.
Despite undisputable successes of the genome-wide approach mentioned above,
GWAS is sometime criticized for its focusing on common SNPs while ignoring rare and
structural variants which may have large effects on complex traits[8][9][10].
Considerable evidence has shown that rare variants and structural variants may have
significant effects on the onset and development of complex disorders, however, this
evidence is selectively omitted and only common variants(minor allele frequency ≥ 0.01)
are considered in GWAS due to a pure statistical concern (to maximize the statistical
8

power in analysis) and genotyping technology limitations[11]. In the past six years, this
challenge has been partly resolved by the development of sequencing technology.
High-throughput sequencing technologies, or so called ―next-generation‖
sequencing(NGS) technologies, which process millions of sequence reads in parallel,
provide monumental increases in speed and volume of generated data at a relatively
acceptable cost[12][13]. Fewer GWAS were published annually since 2012, and this
trend is coincidence with the popularity of sequencing based studies (Figure 1.1).

1.3 Next-Generation Sequencing based Gene Association Mapping:
Promising and Pitfalls
Advancement of DNA genotyping technology has greatly promoted the research of
genetic epidemiology and gene mapping in the last 30 years. Cheaper and faster DNA
genotyping technology enables some once theoretically genetic epidemiology study
designs, such as genome-wide linkage scan and GWAS, to be done. In this sense, NGS
enables the researchers to capture the information of every single variation in the human
genome. The 1000 genome project, a public population genetics project using NGS
technology, has shown that there are more than 88 million variations, including 84.7
million SNPs, 3.6 million short insertions/deletions (indels) and 60,000 structural variants,
in the human genome [14]. Compared to this number, genome linkage scan only involves
about 400 STRs and GWAS only examines 300,000~600,000 common SNPs. The idea of
a whole genome sequencing (WGS) study is preferable to the previous gene mapping
study design in completeness by measuring every variation in human genome. Several
WGS studies focusing on relatively small number of subjects with psychiatric disorders
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[15][16] and cancers [17] [18][19] have been published in high profile academic journals
and novel findings were reported.
Despite its advantage and promising future mentioned above, sequencing-based
association mapping, at least in its current stage, still has two issues left unaddressed.
Firstly, unlike linkage and GWAS, there are no matured statistical analysis methods can
be applied to sequencing data. A major challenge for sequencing based data is that there
are a lot of genetic variants with low allele frequency. That means the single marker
based analysis methods utilized in GWAS cannot be applied directly to sequencing-based
data due to lack of statistical power. A common approach to overcome this issue is to
collapse rare variant information within specific genomic regions (genes, for example),
and these methods are generally called collapsing methods [20][21][22]. I will provide
more details about these collapsing methods and conducted a comparison study to
investigate the efficient of multiple sequencing data analysis methods in Chapter II of this
thesis. The second issue concerns money. Although NGS has greatly reduced the
experimental cost of human genome sequencing, it still takes 5-10 times of experimental
cost to have a human genome sequenced (WGS) compared to genotyped by a microarray
panel (used in GWAS). Two other study design can partly address this issue. The first
one is instead of performing WGS on study subjects, researchers can perform exome
sequencing which only focuses on exonic regions of human genome (1% of the human
genome). This strategy can retain a large amount of genetic information of significant
functional regions while having a much lower experimental cost compared to WGS. I
will present an exome sequencing based study on bipolar disorder in Chapter III. Another
study strategy is to sequence a couple of targeted susceptible genomic regions. On one
10

hand, rare and structural DNA variants of targeted genomic regions can be thoroughly
investigated through DNA sequencing, while on the other hand, the experimental cost can
be restricted to a reasonable level. I will present a targeted sequencing study of nicotine
dependence in Chapter IV.

1.4 Genetic Epidemiology Studies using Insights of Biological Networks
1.4.1 GWAS, WGS and their discontents: hypothesis “free” or “engaged”
Genome-wide approaches are described as ―hypothesis free‖ study designs, because
comparing to the candidate gene based approach, this study strategy does not need prior
knowledge about the candidate genes. A genome-wide scale study enables the genotyped
genetic markers to offer sufficient coverage to most of the human protein coding genes (if
not all) [23]. The ―hypothesis-free‖ basis of genome-wide approaches offered the
opportunity to overcome difficulties and obstacles imposed by the incomplete
understanding of disease pathophysiology. However, despite this ―hypothesis free‖ label,
these genome-wide approaches (including GWAS and WGS) are somewhat dependent on
some underlying hypotheses.
The first underlying assumption is that the genetic risk of complex traits is
contributed independently by genes/variants (assumption of independence). For example,
in GWAS, the simplest analysis strategy is to do logistic regression in a single-locus
manner [23], and in association mapping based on DNA sequencing data, the so-called
―collapsing method‖ was widely utilized for which variants information are often
collapsed within a genomic region or gene and then each region/gene will be tested
pointwisely [21].However, in the past decade, many studies of quantitative traits in
11

animal models suggest that epistatic interactions between loci are widespread[24][25][26],
and various examples of gene-by-gene interactions for human complex traits have been
identified[27].A research study using yeast strains provided an estimated importance of
epistatic interactions for 46 highly heritable traits. It shows that the contribution of
gene-gene interactions (including both two-loci interactions and high order interactions)
varies from zero to ~50% and detected two-locus interactions explain only a minority of
this contribution [28]. In this study, the researchers have used yeast, which is a simple
unicellular organism, as their research subject. We can expect that in some higher level
multi-cellular organisms such as mammals, the patterns of gene-gene interactions will be
more complex. The second assumption is that for GWAS/WGS, different genes are
considered to have equal potentiality to confer the genetic predisposition to the complex
traits (assumption of equality). This assumption has been partly challenged by the
evidence that susceptible genes often show a clustered pattern within certain biological
pathways [29][30]. In addition, previous studies conducted in several different model
organisms [31] have shown that highly connected proteins or ―hubs‖ are more likely to be
encoded by essential genes which are necessary for fundamental processes in an
organism and lead to pre- or neonatal lethality when disrupted.
To conclude, all of the above evidence has indicated that genes are neither created
equally nor perform their functions independently, and novel insights are needed for
understanding the mechanisms of genetic predisposition for complex traits. Other than
simply studying one locus at a time, alternative methods which can carry out global
analyses of biological molecules in populations have been developed to understand the
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influence of the whole biological system on complex traits[32][33]. Network based
approaches, in particular, have proven informative.
1.4.2 Human Gene Networks: Novel Insights into the Genetic Epidemiology Study of
Complex Traits
Human gene networks are graphical representations of the interactions between the
genes. In a human gene network, genes are represented as nodes and the relationships
among them as edges. Human gene networks can be divided into three categories: 1)
Human gene networks derived from curated knowledge; 2) Human gene networks based
on experimental data of physical interactions, and 3) those that are inferred from
high-throughput data [31]. In the past decade, the most interesting finding of gene
network analysis is that proteins that are encoded by essential genes tend to have high
centrality degrees in the protein-protein interaction network. This feature was firstly
identified in yeast [34][35]. Since then, several studies were conducted to focus on the
phenotypes related to human diseases. Wachi et al. studied genes that are differentially
expressed in lung squamous cancer tissues, and found that up-regulated genes in the
cancerous tissues tended to be highly connected and central [36]. Another study in 2006
investigated the network position of 346 genes that had been implicated in a
comprehensive census of all human cancer genes. They showed that on average the
proteins encoded by these genes tended to have twice as many interaction partners as
noncancer related genes [37]. Nevertheless, in a 2007 published research paper, Goh et al.
created a network of human disease/human gene associations, in which each genetic
disease is connected to the genes known to cause it. They found that most of the disease
genes have no tendency toward higher degree in the human protein-protein interaction
13

network [38].One possible explanation for this discrepancy among the studies above is
that the former two studies focused on cancer genes in particular while Goh et al.
investigated disease in general.
Among all these early studies, a significant limitation is that all these studies have
focused on cancer or Mendelian disorders, and the researchers have paid limited attention
to complex disorders. This limitation can be justified by the specific time when these
research projects were conducted. Most of the knowledge of susceptible genes on
complex disorders has been generated after 2007 when GWAS become a standard genetic
epidemiological research strategy on complex disorders. In addition, recent evidence of
interactome networks in the last decade has also questioned the potential incompleteness
in these previous studies. Large scale, comprehensive analysis incorporating with new
findings obtained in the past decade is needed. In chapter 5 of this thesis, I will first
examine the centrality measurements of genes as indicators of their biological
significance in a human general gene network. Then, in chapter 6 I will explore the gene
sets centrality feature for different complex disorders and functional pathways
enrichment patterns in general human gene networks and disease-specific sub-networks.
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1.5 Figures

Figure 1.1 Histogram of GWAS publications by year. The publications of 2015 were
included from January to June.
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1.6 Tables
Table 1.1 Selected human disorders/traits with estimated heritability.
Traits/Disorders

Heritability (%)

Acne

81

Age-related macular degeneration

49 - 71

Alcoholism

50 - 60

Alzheimer's disease

58 - 79

Asthma

30

Attention deficit hyperactivity disorder

70

Autism

30 - 90

Bipolar disorder

70

Bladder cancer

7 - 31

Blood pressure, diastolic

49

Blood pressure, systolic

30

Body mass index

23 - 51

Bone mineral density

44 - 87

Breast cancer

25 - 56

Celiac disease

57 - 87

Cervical cancer

22

Chronic obstructive pulmonary disease

76

Colon cancer

13

Coronary artery disease

49

Depression

50

Epilepsy

70 - 88

Eye color

98

Heart disease

34 - 53

Height

55 - 81

Hypertension

30

Leukemia

1

16

Longevity

26

Lung cancer

8

Nicotine dependence

60

Obesity

70

Ovarian cancer

40

Parkinson's disease

25 - 30

Periodontitis

42

Prostate cancer

42

Psoriasis

66

Schizophrenia

81

Stomach cancer

1

Stroke

32

Testicular cancer

25

Thyroid cancer

53

Type-1 diabetes

88

Type-2 diabetes
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Data source: SNPpedia(http://www.snpedia.com/index.php/SNPedia).
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Chapter 2: Application of Non-collapsing
Methods to Gene-based Association Test
2.1 Introduction
Unlike GWAS which focuses on common SNPs that have relatively higher MAF,
sequencing based association study could generate tons of rare or low frequency variants
and traditional statistical methods often fail in association mapping due to poor statistical
power. To address this issue, as introduced in Chapter I, one commonly utilized strategy
is to collapse rare variants information within specific genomic regions (such as genes),
and this ―super marker‖ will be tested statistically[20][ 21][ 22]. This strategy could
partly solve the issue of statistical power, however, it has assumes the directions of the
effects of DNA variants are consistent, and this assumption may not be true. Compared to
these collapsing methods, the non-collapsing methods, which do not require the
assumption of consistency of effects direction, may be more reasonable choices for rare
variants based association mapping.
In this chapter, we proposed a two-stage, gene-based method for association
mapping of rare variants by applying four different non-collapsing algorithms using the
whole genome sequencing dataset and simulated blood pressure phenotype of genome
analysis workshop (GAW) 18[39]. Genetic analysis workshop provided a platform for
developing and evaluating statistical methods to analyze population and family based
human genetics data. It is held every other year. GAW18 focused on identification of
genes and functional variants that influence complex phenotypes in human sequence data.
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In this research we will first obtain significance P values by fitting a mixed effects
model for each variant, and then apply four non-collapsing algorithms, including Fisher’s,
gene set enrichment analysis (GSEA), sequence kernel association test (SKAT), to
obtain the gene-wise association P values. Collapsing (or burden) methods combine
variant information by assuming consistent direction of effects across variants. None of
the methods considered here adopt this assumption, although some do combine variant
information.

2.2 Materials and Methods
2.2.1 Model fitting and algorithms
A mixed linear model was fitted for each variant as described in previous
literature [40]. The model was defined as:

Y  X   Q  Z    （2.1）,
where Y is the quantitative trait of interest (we used first-visit systolic blood
pressure [SBP]); X is the genotype; β is the fixed effects of the genotypes; and Q
represents the population structure variables . In this study, we chose the first 10 principal
components from principal component analysis (PCA) for Q. ν is the fixed effects of Q; Z
is the variable that evaluates familial relatedness (the theoretical kinship matrix was used
for Z); and µ is the random effects coefficient for Z that corrects the polygenic impact.
After obtaining the variant-wise P values by fitting the mixed linear model shown
above, four non-collapsing algorithms were modified and applied to the data set to obtain
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the gene-wise association P values. The algorithms of the four methods are summarized
as followed:
1. Naïve method. The most significant variant-wise P values within a specific
gene were chosen as the gene-wise association P values.
2. Fisher’s method [41]. The gene-wise statistics were calculated through the
following equation:
k

X  2 log e ( pi )

（2.2）,

i 1

where pi is the p value for variant i, and k is the total number of variants within a
specific gene. Because many variants are highly correlated, the basic assumption of
independent tests for Fisher’s method is violated. Fisher’s formula may not have a
chi-square distribution, so we assessed the significance via permutations.
3. Simes’ method [42]. The gene-wise p value was summarized by the following
equation:

Psimes  min{
i

kpi
}
i

（2.3）,

where pi is the p value for variant i, and k is the total number of variants within a
specific gene.
4. GSEA method [43][44]. The test statistics (indicated as ES score) were
aggregated from variant-wise p values within each gene via a Kolmogorov-Smirnov–like
process in which running sums are accumulated. The equation is given as:
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ES ( S )  max{
1 j  N

r( j*)



G j *S , j * j

p



NR

1
}
G j*S , j * j N  N H



（2.4）

where N is the total number of variants, r(j) is the jth largest statistic values, NH is
the variant number of a given gene, S is any given gene, P is the parameter that gives a
higher weight to variants with extreme statistic value, arbitrarily set to 1 in this study, and
NR is given by:

N R  G

j *S

r( j *)

p

（2.5）

Statistical significance and adjustment for multiple hypothesis testing were
assessed by a 1000 permutation based procedure. A family-wise error rate (FWER)
procedure was used to adjust for multiple-hypothesis testing. In this study, the FWER p
value was calculated as the fraction of all permutations whose highest statistics (or
smallest p values) in all genes is higher than a given gene. In addition to the four
non-collapsing algorithms introduced above, we also included two standard rare variants
based methods: SKAT [21] and famSKAT [45] in our analysis. FamSKAT is an extended
version of SKAT and can be utilized to analyze rare variant when family correlations are
present. Furthermore, to evaluate the statistical power of these methods, we extracted the
variant information related to the 22 true-positive genes located on chromosome 3 and
analyzed these data for all 200 simulated phenotype replicates.
2.2.2 Data and computation
We only analyzed one phenotype replicate and sequencing data of chromosome 3
due to the huge computational burden. The sequencing data were annotated by
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ANNOVAR [46]. Intergenic variants (variants at least 1 kilobase [kb] away from any
known gene regions) were excluded, but variants that can be mapped to regulatory
regions (ORegAnno) were kept [47].
To preserve the familial structure, a permutation-of-residuals procedure was
applied [48]. First, we fitted a mixed effects linear model on the phenotypic data with all
the covariates in the model (except for genotype term) and preserved the residuals for
these models. Second, we shuffled the residuals (rather than the phenotypic data used in
an ordinary permutation procedure) and randomly assigned them to each subject and
generated 1000 phenotypic data replicates. And third, we obtained the permuted statistics
and p values by fitting a univariate linear model with genotype as the only predictor of
the residuals. This method may introduce potential bias to the permuted statistics and p
values comparing to directly fitting the full model. To quantify this potential bias, we
randomly chose 1429 variants and calculated the percentage difference of the −log10
scaled p values obtained from directly fitting a full model and from the two-step
permutation procedure proposed above. The results of the permutation bias analysis
showed that the percentage difference was only approximately 10%, and the correlation
coefficient of variant-wise statistics was 0.9959. These results indicate that the effects of
this bias are limited.
Genotypes were coded in dominant model. That is, the genotypes with 1 or 2
minor alleles were coded as 1, while genotypes with 2 major alleles were assigned 0.
Variants with minor allele frequency >0.3 in genome-wide association data set were
selected for PCA. We used Eigenstrat 3.0 for this analysis [49]. The R package kinship2
(http://cran.r-project.org/web/packages/kinship2/index.html) was used to calculate the
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kinship coefficient matrix for our data set. The R package coxme
(http://cran.r-project.org/web/packages/coxme/index.html) was implemented for fitting
the mixed linear model. The R package SKAT
(http://cran.r-project.org/web/packages/SKAT/index.html) was implemented for rare
variant analysis with SKAT. The R source code for famSKAT was downloaded
(http://www.bumc.bu.edu/linga/research/publications/famskat/) and implemented for rare
variant analysis. Receiver operating characteristic (ROC) curves were made and
compared among the four algorithms and two standard methods.

2.3 Results
The data consisted of 1,237 genes with 87,190 variants that passed the annotation
criteria were extracted from the sequencing data set of chromosome 3 for 849 subjects.
After fitting the mixed linear model, the Q-Q plot and histogram of p values of these
87,190 variants is shown in figure 2.1. Data for the 22 true positive (true answer) genes
with 1,098 variants were extracted and used for analysis with 200 simulated phenotype
replicates. The statistical power information for all the six methods was summarized and
is presented in table 2.1. From the power analysis results, we see that the gene MAP4 was
successfully identified to be significant for all simulated 200 replicates.

All six methods

achieved 100% power for this gene. For the rest 21 genes, the largest power was 27.5%,
which was achieved by SKAT for LOC152217.
To compare the four non-collapsing methods and the two standard methods, ROC
curves based on these six methods were constructed and shown in figure 2.2. From this
fugure we noted that, overall, the Simes’ method performed a little better compared to the
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other five methods, and that GSEA, SKAT and famSKAT did not perform as well as
Simes’ method. The other two methods were slightly better than GSEA, SKAT and
famSKAT method. However, when we limited the false positive rate to be smaller than
0.1 as shown in the right hand plot of figure 2.2 (in practice, only a high true positive rate
with a low false positive rate is of interest), we see that Fisher’s method and famSKAT
performed better than other methods at the low false positive rate range. They both
capture around 15% of the causal genes (true positives) with a cost of only 5% false
positive signals. However, we did not test the significance of the ROC curves, so that all
these observed differences could just be noise.

2.4 Discussion and Conclusion
MAP4 was identified to be the causal gene with 100% statistical power. This
result is reasonable since, according to the ―answer sheet‖ of GAW18, MAP4 contains
the most ―causal variants‖ and these variants have a relatively larger effect size
comparing to the variants within other genes. However, this result was obtained when
we only analyzed the 22 ―true answer‖ genes. For a genome-scale analysis, the
significant signals may be missed due to correction for multiple comparisons. We have
also analyzed the whole genotypic dataset of chromosome 3 with simulated phenotypic
replicate #1(including 1,237 genes and 87,190 variants). The result indicated that only
naïve method and the two standard methods identified gene MAP4 to be significant.
The non-collapsing methods introduced in this paper have been broadly utilized in
testing the significance of biological pathways in GWAS datasets. When we substitute
the term ―pathway‖ in these non-collapsing algorithms for the term ―gene‖ in sequencing
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analysis and ―gene‖ for ―variants‖, we can apply these non-collapsing algorithms to
gene-based association detection through modifications. An obvious advantage of
aggregating p values (or statistics) by applying non-collapsing algorithms compared to
ordinary variants collapsing methods is that it is a method free of the assumption that all
the causal variants from a gene have effects in the same direction. This assumption may
not be held in many scenarios even though it is the assumed in many existing rare
variants association mapping procedures.
In this study, we utilized the residuals-of-permutation procedure to deal with our
familial based data. Conducting a permutation on family data has been a challenge in
statistical genetics research. Ordinary permutation procedures have been mostly utilized
in case-control data, which simply shuffle the phenotypic data and randomly assigns
them to each subject, thus cannot be directly applied to family data because it destroys
the family structure. In our research, instead of shuffling the phenotypic data, we shuffled
the residuals obtained from fitting a linear mixed effects model without genotype. These
residuals have already accounted familial relatedness in the model fitting step and
therefore our permutation procedure preserved the familial structure.
Several previous researchers have already applied the non-collapsing methods
proposed in our research to conduct gene-based analysis [50][51]. However, these
previous works have mainly focused on common variants in GWAS dataset. As an
attempt to apply these non-collapsing algorithms to gene-based association tests using
sequencing data, we have demonstrated some potentially promising aspects of this
approach. However, several problems remain unaddressed. One important issue is the
computational intensity. In this study, we have utilized a multi-processor-computing
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server with 23×2.8 GHz CPU and 64GB memory in total. The most time consuming part
of our analysis is the permutation-of-residuals process and linear model fitting of the
permuted datasets. We have paralleled this process into 20 jobs, but it still takes around
30 hours to complete (this is only the work done for one chromosome). Compared to the
permutation process, the p value combination step can be completed much faster (~30
minutes). Since a lot of the non-collapsing algorithms require permutation procedures to
create null distribution of the statistics, it is somewhat difficult to implement them on
genome-wide scale dataset. In addition, many non-collapsing algorithms cannot be
utilized for a gene-based association test directly without proper modifications. The
choice of parameters in non-collapsing algorithm for rare variant association detection is
more an art than a science. Finally, adjustment for multiple hypothesis testing is another
important issue that needs to be addressed. Our results indicate that the FWER method is
too conservative. For the future work, hierarchical modeling combined with MCMC may
provide better solution to the multiple hypothesis testing problems [52].
To conclude, in this study, we showed that the statistical efficiency of several
sequencing data based methods were not very promising, although some of them were
commonly utilized in sequencing data analyzes as standard methods. Further
investigation is needed to explore the potential statistical properties of these approaches.
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2.5 Figures

Figure 2.1 Q-Q plot and histogram for the mixed effects model. Q-Q plot (left) of –log10
scaled p-values and histogram (right) for the mixed effects model based on 1,237 genes
(87,190 variants) from 849 subjects. In Q-Q plot, black line, expected; blue dots,
observed.
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Figure 2.2 ROC curves for four non-collapsing algorithms and two standard methods.
ROC curves for four different pathway algorithms based on 1,237 genes from 849
subjects on trait SBP (first visit). In the left plot FPR ranges from 0 to 1. In the right plot
FPR is scaled to be less than 0.1 since only the true positive rate (TPR) with a low FPR is
of interest. Black curve, naïve method; blue curve, Fisher’s method; red curve, Simes’
method; green curve, GSEA method; purple curve, SKAT; yellow curve, famSKAT.
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2.6 Tables
Table 2.1 Comparison of the statistical power of the four non-collapsing and two standard methods.
CHR

Gene

Power of Methods
Naïve Method

Fisher’s Method

Simes’ Method

GSEA Method

SKAT

FamSKAT

0.015

0.18

0.025

0

0.075

0.01

3

ABTB1

3

ARHGEF3

0

0

0

0.035

0.005

0.005

3

B4GALT4

0.015

0

0.015

0.035

0.01

0.015

3

BTD

0

0

0

0.015

0

0

3

CXCR6

0

0

0

0.085

0

0

3

DNASE1L3

0.005

0.005

0.005

0.005

0.04

0.01

3

FBLN2

0.005

0

0

0.035

0

0

3

FLNB

0.01

0.015

0

0.03

0

0

3

LOC152217

0.09

0.145

0.135

0

0.275

0.04

3

MAP4

1

1

1

1

1

1

3

NMNAT3

0.005

0.04

0.005

0

0

0

3

PAK2

0.07

0

0.05

0

0

0

3

PDCD6IP

0.005

0

0.005

0.005

0.04

0.03

3

PPP2R3A

0.045

0.01

0.02

0

0.005

0.005

3

PTPLB

0

0

0

0.02

0.005

0
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3

SCAP

0.025

0.005

0.04

0

0.045

0.065

3

SEMA3F

0

0

0

0

0

0

3

SENP5

0

0.02

0.01

0.045

0.01

0.005

3

SUMF1

0.085

0.005

0.06

0.01

0.015

0.005

3

TFDP2

0

0

0

0.035

0

0

3

TUSC2

0.005

0

0.055

0

0.02

0

3

ZBTB38

0.01

0.005

0.01

0.02

0.04

0

Power is calculated based on the analysis of the 200 simulated phenotypic replicates. The largest power for each gene is highlighted in
bold.
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Chapter 3: Family-based Whole Exome
Sequencing Study for Bipolar Disorder
3.1 Introduction
3.1.1 Clinical and epidemiological characteristic of bipolar disorder
Bipolar disorder (BPD) is a mental illness with lifetime prevalence of about 1%
[53]. BPD is characterized by periods of elevated mood (manic/hypomanic episodes) and
periods of depression (depressive episodes) [54]. Currently, there is no cure for BPD, and
medications and therapies are used to treat the symptoms. Patients with BPD and their
families experience significant losses in functional status and quality of life, placing
untoward stress on personal relationships. In addition, BPD is one of the most expensive
mental health care diagnosis, both for patients with the illness and for their health
insurance plans [55], and that in turn adds a financial burden on the patients’ families, as
well as on society as a whole. Biomedical and etiological studies on the onset and
development of BPD can throw light on new drug discovery and therapy development.

3.1.2 Gene association mapping of bipolar disorder: a brief review
The etiology of BPD is not clearly understood but extensive research has
indicated that both genetic and environmental factors play a role [56]. Familial clustering
studies have identified a ten-fold higher risk of BPD in people who have affected first
degree relatives when compared to the general population [56]. The heritability of overall
bipolar spectrum disorders is estimated to be 0.71[57]. More than 40 linkage scans for
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BPD have been published and implicate many areas of the genome, although several
studies have inconsistent results [56]. Genome-wide association studies (GWAS) have
identified several susceptibility loci including markers near PALB2 [58], DGKH [59],
ANK3& CACNA1C [60], 3p21 [61], NCAN [62], ODZ4 [63], TRANK1& LMAN2L [64],
ADCY2&6q16 [65], and SESTD1 [66]. Nevertheless, despite these findings, a recent
study has estimated the SNP heritability (the proportion of variation in disease liability
that is captured in GWAS by considering all SNPs simultaneously) was ~0.4 for BPD
[10]. This indicates that further research is needed to unravel the genetic etiology for
BPD.
The traditional microarray chip technology based GWAS focuses on common
variants (genetic variants that have minor allele frequency at 5% or higher), and
selectively omits the rare variants and structural variants such as short insertion and
deletions (indels) due to technological problems [67]. The recent development of
―next-generation‖ sequencing technology has enabled researchers to investigate these
variants which are not covered in GWAS at a relatively lower genotyping cost [68].
Exome sequencing, which sequences the exons of protein coding genes in the genome, is
considered to be a powerful tool in genetic association research [69]. By focusing only on
the region of exons, exome sequencing only sequences around 1% of the human genome
(far less than whole genome sequencing) while investigating genomic regions of
functional significance. A recent research project focusing on lithium-responsive bipolar
disorder has identified several rare susceptibility variants by exome sequencing analysis
based on 36 familial samples [70]. This result indicates that exome sequencing
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technology combined with proper study design is a promising method for association
mapping.
In this chapter, we have recruited six related BPD cases from a single BPD
extended family. The rationale is that a single variant is segregating in this large, unusual
family and that this approach will minimize genetic heterogeneity by restricting analysis
to a single family. We have performed whole exome sequencing on the six BPD cases,
and examined the DNA variants that are shared among all these six cases. Additionally,
we have also performed a genome-wide high density linkage analysis based on common
SNP data. The linkage peak region has further narrowed down the potential susceptibility
variants and genes for BPD.

3.2 Materials and Methods
3.2.1 Study subjects
The BPD family was selected via a history of multiple relatives with BPD. An
index case was recruited from department of psychiatry at Barnes-Jewish Hospital.
Relatives were diagnosed via diagnostic interview (SADS-L) and two independent senior
psychiatrists gave best estimated diagnosis made through consensus. Signed consent
forms were obtained from all the recruited members. This study was approved by IRB of
Washington University in St. Louis. The pedigree structure of the family recruited in this
study was shown below (figure 3.1). Six subjects with BPD were included in this study.
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3.2.2 Experimental Methods
Genomic DNA was isolated from the peripheral blood leukocytes and the DNA
was stored at −80 °C for genotyping. The microarray genotyping was done by Illumina
OmniExpress. We applied quality control process to remove singletons and SNPs with
missing rate higher than 10%. The whole-exome sequencing was carried out using
Agilent SureSelect All Exon 50Mb Target Enrichment kit and on the SOLiD System by
EdgeBio.

The average read depth for the six bipolar subjects were 57x. For the

exome-seq data, the alignment was done using novoalignCS (V1.01.15) by EdgeBio, and
the data were recalled with HaplotypeCaller (GATK v3.3) [71]. The QC was done by
GATK¹s VQSR.

3.2.3 Statistical methods
We implemented parametric linkage analysis based on the software Merlin [72] to
identify potential linkage peak regions with the pedigree data. The allele frequency data
were extracted from Hapmap 2 CEU samples. SLINK [73] was used to simulate the
linage analysis to obtain a LOD score threshold with acceptable statistical power. The
potential effects of exonic SNVs were predicted using SIFT [74] and Polyphen2 [75].
The redundancy of the microarray SNP chip panel enables us to implement a
10-set replicate analysis strategy in order to reduce the number of potential false positive
signals obtained from the linkage analysis. We 1) randomly selected 10 sets of SNPs with
considerations of minor allele frequency (MAF> 0.3), Linkage disequilibrium (LD)
structure (to account for LD) and their genomic coverage (each SNPs set contains around
10,000 markers); 2) conducted linkage analysis with each of these 10 replicated SNP sets
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independently; and 3) identified the peak regions that are repetitively identified in all of
the ten rounds of analysis. To account for the potential impact of LD on linkage signals,
we only chose one SNP from each LD block which was constructed based on the
Hapmap European population data. The LD block was estimated using Plink [76].
We implemented the Perl based software ANNOVAR[46] to annotate the exome
sequencing data. To investigate the potential susceptibility variants/genes within this
large family, we extracted variants that 1) pass the quality control criteria specified in
GATK software; 2) are under one of the linkage peak regions; 3) located within genetic
region with functional significance (splicing site variants, non-synonymous SNVs, stop
gain SNVs, frameshift indels, or non-frameshift indels within exonic regions) and 4)
Only variants that were not recorded in 1000 genome database or variants with recorded
MAF < 0.05 were included. We also incorporated our filtering results with R package
RVsharing [77] to have a statistical estimate of our observed excess sharing among all the
related BPD cases of those candidate variants.

3.3 Results
3.3.1 Results of linkage analysis
Simulation of the linkage analysis with SLINK showed that a LOD threshold 2.0
will only achieve 22% statistical power. To increase statistical power, we chose 1.8 as the
LOD threshold with the cost of increasing the false positive rate. To control the number
of potential false positive linkage signals, we implemented a 10-replicate linkage analysis
strategy. Genotypes data were released for 733,202 SNPs with our Illumina microarray
chip and 537,258 were left after quality control. The redundancy of these markers
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enabled us to implement a 10-replicate analysis strategy to reduce the number of the
potential false positive linkage signals. This marker sets selection and analysis
implementation was as indicated above.
The linkage analysis results of 10 replicate SNP sets are shown in table 1. As
shown in table 1, four peak regions in total were identified from the linkage analysis.
They are 5q33.1- 5q 33.3, 5q35.1-5q35.2, 10q21.1-10q21.2 and 10q23.1-10q23.33. Two
of these 4 linkage peaks, 5q33.1- 5q 33.3 and 5q35.1-5q35.2 (figure 3.2) were only
identified 3 and 1 times, respectively. This indicates that these two linkage peak signals
may be false positive signals. The two consecutive peak regions on chromosome 10,
10q21.1-10q21.2 and 10q23.1-10q23.33 (10q22.3-10q23.33) were identified multiple
times in the 10 replicate sets and 10q23.1-10q23.33 (10q22.3-10q23.33) was identified
repetitively in all of the 10 replicate SNP sets. This result indicates that the chance that
this peak region is a false positive signal is very low (figure 3.3). Here we provide a
brief estimation for the false positive rate of this peak region. The LOD threshold we
used here is 1.8, and this is approximately equal to p value <0.002 [78]. Although we
tested around 10,000 SNPs, considering the potential LD among SNPs, the independent
number of tests might be around 400 (this is a reasonable estimate because 400 is the
number of tests when using microsatellite markers for linkage analysis). Therefore, the
false positive rate for each replicate is around 0.55 (1-0.998400). For a genomic region
that is proved to be significant in all of the ten replicates, its false positive rate can be as
low as 0.0025 (0.5510). Therefore we concentrated those variants under this peak region
(10q23.1-10q23.33) on chromosome 10. We have summarized the results of linkage
analyses of each marker set in table 3.1.
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3.3.2 Results of variants filtering
Genotypic data were released for 140,814 variants (table 3.2). Among the 140,814
variants, 114,432 (81.26%) variants passed the quality control specified in GATK
software. Within these high quality variant calls, 444 variants were located under the
linkage peak region of chromosome 10. The number of variants was reduced to 60 if we
only considered those variants with potential functional significance. Among these 60
variants, a total of 15 variants were not recorded in 1000 genome database or were rare
variants with MAF less than 0.05 according to 1000 genome data in Caucasian
population. Nine out of these 15 variants were only identified in one of six bipolar
subjects sequenced, and 6 variants were shared by 2, 3 or 4 individuals. We have
summarized the information of these 6 variants in table 3.3. Tests of RVSharing indicated
that three out of these six variants (shared among 3 or 4 patients) were statistically
significant with P value <0.008 (0.05/6). The other three variants that were shared among
two patients had a P value of 0.0695. These 6 variants come from 5 genes including
DYDC2, GHITM, MINPP1, CDHR1 and GRID1. Two SNVs located in the genes
CDHR1 and GRID1 were predicted to be ―damaging‖ or ―possibly damaging‖ by SIFT
and Polyphen-2.

3.4 Discussion and Conclusion
Our aim was to identify potential susceptibility variants that contribute to the risk
of BPD. In order to minimize genetic heterogeneity, we restricted analysis to a single
large family in which several distantly-related individuals suffer from BPD. If a single
variant affecting risk for BPD is segregating in this multiply affected family, this
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approach should identify the variant within the larger set of segregating variants,
nominating candidate genes for future studies.
We narrowed the targeted genomic region down to a ~15 MB region by restricting
the analysis to a linkage peak identified on chromosome 10. This region (10q22) has been
previously reported to be linked with BPD in a large scale linkage study by Fallin et al
[79]. After filtering for minor allele frequency, sharing among affected relatives, and
functional significance of the potential susceptibility variants, we identified a list of 6
variants within 5 genes. A total of 3 variants in 2 genes, GRID1 and CDHR1, were
identified in 2 of the 6 BPD cases. The two cases that shared these 3 variants are also first
cousins within this four generation pedigree (individuals #142 and #5 from (figure 3.1).
GRID1 encodes a subunit of glutamate receptor channels. These channels mediate most
of the fast excitatory synaptic transmission in the central nervous system and play key
roles in synaptic plasticity [80]. GRID1 has been widely investigated in multiple
psychiatric disorders and brain related traits [81][82][83][84]. It was first reported by
Fallin et al. that GRID1 was significantly associated with schizophrenia and associated
with BPD with suggestive significance among Ashkenazi Jewish case-parent trios [81].
A study of mice in which the GRID1 homologue, GluD1, was knocked out reported that
the mice were hyperactive, manifested lower anxiety-like and depression-like behavior,
and robust aggression [85]. The two rare GRID1 variants we report here (rs2306265
and rs3812645) represent the first evidence that rare variants in GRID1 may contribute to
BPD.
The other gene with a shared rare variant, CDHR1, belongs to the cadherin
superfamily of calcium-dependent cell adhesion molecules. Its encoded protein is a
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photoreceptor-specific cadherin that plays a role in outer segment disc morphogenesis
[86]. Mutations in this gene have been associated with recessive retinal degeneration [87]
and autosomal recessive cone-rod dystrophy [88]. However, no previous study has linked
this gene to any psychiatric disorders. We also identified 3 interesting variants in DYDC2,
GHITM and MINPP1. These variants were predicted to be ―benign‖ or ―tolerated‖ and
might not affect the protein structure. However, all of these variants were shared by 3 or
4 BPD cases in this pedigree, and their sharing patterns were significant after Bonferroni
correction using the RVsharing algorithm.
We note that, given our sample size, these P values can only be used as a
suggestive guidance when prioritizing variants for further study. One major strength of
our study is that as an exome sequencing based study, we can examine both common and
rare variants. Previous association studies on BPD mainly focus on common SNPs while
ignoring most of the low frequency and rare variants. Restricting to common SNP, may
hinder the ability to find susceptibility variants or genes. In our study, we considered both
rare and common functional variants via exome sequencing technology. In addition, an
advantage of our family based study design is that rare variants that segregate with
reasonably high penetrance in an extended pedigree can provide a linkage signal helpful
in identifying the susceptibility genes.
There are also several limitations of our study. A main limitation is that we lack
familial controls. The variant sharing we utilized as a filtering strategy in our study might
generate some false positive signals due to relatives sharing neutral DNA variations.
Having exome sequencing data from several healthy family members of this pedigree
might further narrow down our candidate gene list. It is still too early for us to make any
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conclusion on the potential role played by these candidate genes in the onset and
development of BPD. Limited by our sample type and study design, further research is
needed to replicate our finding in unrelated individuals. More research is needed to reveal
the potential relationship of our candidate gene list and biological mechanisms of BPD.
In summary, our study identified a list of 5 potential candidate genes for BPD
based on exome sequencing in a large bipolar disorder pedigree. Among these 5 genes,
GRID1 has been reported to be associated with several psychiatric and brain related traits
in common SNP-based studies. Our results provide some evidence linking rare variation
in GRID1 with BPD. These findings suggest a potential role for these genes in the risk
for BPD, but require replication in large, independent studies.
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3.5 Figures

Figure 3.1 Pedigree structure of the BPD family sequenced in this study. Blood samples
of the 6 BPD cases at the bottom of the pedigree were collected.
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Figure 3.2 Significant peak regions identified on chromosome 5 in three sets of linkage
analysis. a. Linkage results for chromosome 5 using SNP set #4 with 10,058 SNPs; b.
Linkage results for chromosome 5 using SNP set #6 with 9,715 SNPs; c. Linkage results
for chromosome 5 using SNP set #8 with 10,402 SNPs. Two peak regions 5q33.1- 5q
33.3 and 5q35.1-5q35.2 were identified 3 and 1 times respectively. The LOD threshold
was indicated in dotted line.
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Figure 3.3 Significant peak regions identified on chromosome 10 in all the ten sets of
linkage analysis. a. Linkage results for chromosome 10 using SNP set #1 with 10,396
SNPs; b. Linkage results for chromosome 10 using SNP set #2 with 9,648 SNPs; c.
Linkage results for chromosome 10 using SNP set #3 with 9,963 SNPs; d. Linkage results
for chromosome 10 using SNP set #4 with 10,058 SNPs; e. Linkage results for
chromosome 10 using SNP set #5 with 10,407 SNPs; f. Linkage results for chromosome
10 using SNP set #6 with 9,715 SNPs; g. Linkage results for chromosome 10 using SNP
set #7 with 10,418 SNPs; h. Linkage results for chromosome 10 using SNP set #8 with
10,402 SNPs; i. Linkage results for chromosome 10 using SNP set #9 with 10,236 SNPs;
j. Linkage results for chromosome 10 using SNP set #10 with 10,402 SNPs. Chromosome
region 10q21.1-10q21.2 and 10q23.1-10q23.33 (10q22.3-10q23.33) were identified
multiple times in the 10 replicate sets and 10q23.1-10q23.33 (10q22.3-10q23.33) was
identified repetitively in all of the 10 replicate sets. The LOD threshold was indicated in
dotted line.
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3.6 Tables
Table 3.1 Linkage analysis results of the ten replicate sets.

Set

# of markers

Chromosome Regions

LOD

1

10,396

10q22.3-10q23.33

1.92

2

9,648

10q21.1-10q21.2

1.91

10q22.3-10q23.33

1.92

10q21.1-10q21.3

1.91

10q22.3-10q23.33

1.93

5q33.1-5q33.2

1.88

10q21.1-q22.3

1.91

10q23.1-10q23.33

1.92

10q21.1-10q21.2

1.91

10q23.1-10q23.33

1.92

5q33.1- 5q 33.3

1.9

5q35.1-5q35.2

2.77

10q23.1-10q23.33

1.92

10q21.1-10q21.2

1.91

10q23.1-10q23.33

1.92

5q33.1- 5q 33.2

1.9

10q21.1-10q21.2

1.91

10q23.1-10q23.33

1.92

10q21.1-10q21.2

1.87

10q23.1-10q23.33

1.92

10q21.1-10q21.2

1.9

3

4

5

6

7

8

9

10

9,963

10,058

10,407

9,715

10,418

10,402

10,236

10,402

10q23.1-10q23.33
1.92
The most significant linkage peak region was found on chromosome region
10q22.3-10q23.33 with LOD score of 1.926. The LOD threshold is 1.8.We have
highlighted the 10q23.1-10q23.33 which were identified to be significant in all ten SNP
replicates.
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Table 3.2 Filtering procedure applied to the exome sequencing data from 6 BPD relative
cases.

Filtering Procedure

Number of Variants pass QC (%)

Genotype calls released

140,814 (100)

Quality Control

114,432 (81.26)

Linkage Peak Region

444 (0.32)

Variants with functional significance

60 (0.04)

Novel variants or variants with MAF less than 0.05

15 (0.01)

The number of variants is reduced to 15 from the 140,814 released by exome sequencing
by applying various filtering strategies.
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Table 3.3 Summary information for 6 genetic variants identified after applying the filtering strategy.

CHR

Ref

Alt

Gene

Function

AAChange

SIFT*

C

G

DYDC2

nonsynonymous SNV

p.P123R

T

B

4

0.0003

85902497

A

T

GHITM

nonsynonymous SNV

p.E72D

T

B

4

0.0003

10

rs45584033 85974231

C

T

CDHR1

nonsynonymous SNV

p.P812S

D

D

2

0.0695

10

rs2306265

87484382

C

T

GRID1

nonsynonymous SNV

p.V529I

D

D

2

0.0695

10

rs3812645

87489317

T

C

GRID1

nonsynonymous SNV

p.M430V

T

B

2

0.0695

10

-

89280872

C

T

MINPP1

nonsynonymous SNV

p.T137I

T

B

3

0.003

10

10

SNP

Position

rs36027713 82126541

-

Polyphen2** Sharing

* SIFT prediction. T stands for tolerated and D stands for damaging.
** Polyphen2 prediction. B stands for benign, P stands for possibly damaging, and D stands for probably damaging.
*** P values here stands for the probability of observing the sharing pattern in our pedigree. Significant variants after applying
Bonferroni correction were shown in bold.
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Chapter 4: Targeted Sequencing
Identifies Genetic Polymorphisms of
Flavin-containing Monooxygenase
Genes Contributing to Susceptibility of
Nicotine Dependence in European and
African Americans
4.1 Introduction
4.1.1 Clinical and epidemiological characteristic of nicotine dependence

Smoking is a leading cause of preventable death, causing about 5 million
premature deaths worldwide each year, and current trends show that tobacco use will
cause more than 8 million deaths annually by 2030 [89]. Strong evidence connects
cigarette smoking and lung cancer [90][91][92], and according to the data from
American cancer society, lung cancer causes the most death each year compared to
other cancers [93]. In addition, cigarette smoking is also the principal environmental
risk factor for developing chronic obstructive pulmonary disease (COPD), a disease
characterized by chronically poor airflow [94][95][96] . Therefore, understanding the
underlying biological mechanisms of nicotine dependence will still have huge public
health significance in the future.
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4.1.2 Gene association mapping of nicotine dependence: a brief review

Early studies based on samples of twins have linked the lifetime smoking
practices to genetic predisposition [97]. A meta-analysis of the data from five studies,
each involving more than 1,000 twin pairs, showed an estimated heritability of 60%
for the propensity to smoke [98]. The followed linkage and gene association mapping
studies have identified several susceptible loci, including genes encoding dopamine
transporter/receptors [99][100][101], cholinergic receptors [102][103][104][105] ,
taste receptor [106] , serotonin receptor [107][108] and gamma-aminobutyric acid
type B receptor [109], that are associated with nicotine dependence. The breakthrough
of microarray technology at the end of 20th century enabled the ―unbiased‖
association mapping analysis in the whole human genome. Genome-wide association
study (GWAS), which scans the whole genome by capturing the information of
common SNPs, has been proved informative for nicotine dependence
[110][111][112][113], and greatly accelerates the progress of this gene hunting
process.

Nevertheless, GWAS only focuses on a set of pre-selected, generally

common SNPs, and tends to omit the rare variants and structural variants such as
short insertion and deletions (indels). The recent development of ―next-generation‖
sequencing technology has enabled researchers to investigate these variants which are
not covered in GWAS at a relatively lower genotyping cost [114][115][116]. A recent
published study focusing on targeted sequencing data of CHRNA5 has identified
several novel rare and low frequency coding variants that contributed to nicotine
dependence [117].
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Three protein families are involved in nicotine pharmacokinetics: liver
cytochrome P450 enzymes (CYPs), flavin-containing monooxygenases (FMOs) and
uridinediphosphate glucuronosyltransferase enzymes (UGTs) [118]. The
flavin-containing monooxygenase (FMO) protein family consists of a group of
enzymes that metabolise drugs and xenobiotics [119]. Five forms of FMOs are found
in human and have been designated FMO1-FMO5 [119]. Among these FMO genes,
part of nicotine inhaled during smoking can be broken down to N′-oxide by
flavin-containing monooxygenase 3 (encoded by FMO3) [118]. Hinrichs et al. has
identified significant association between SNPs of FMO1 and nicotine dependence
[120]. Although a recent study has shown that common polymorphisms in FMO3 can
influence nicotine clearance [118], no study has provided direct evidence of the
association between FMO3 polymorphisms and nicotine dependence.

In this chapter, we investigated the potential of FMO genes to confer risk of
nicotine dependence via deep targeted sequencing in 2,820 study subjects (1,432
European and 1,388 African Americans) comprising of 1,583nicotine dependents and
1,237controls. Specifically, we focused on the two genomic segments including
FMO1, FMO3 (protein coding genes for flavin-containing monooxygenase 1 and 3)
and FMO6P (pseudo gene), and aimed to investigate the potential association between
FMO genes and nicotine dependence. Via implementing targeted sequencing, we are
interested to figure out that whether rare variants contribute to the association signal
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derived from common variants. In addition, comparisons were made between the
association results based on European Americans and African Americans.

4.2 Materials and Methods
4.2.1 Study subjects

This research was reviewed and approved by the Institutional Review Board at
Washington University in Saint Louis. All the study subjects provided informed
consent. Study subjects were recruited from Collaborative Genetics Study of Nicotine
Dependence (COGEND) and the Genetic Study of Nicotine Dependence in African
Americans (AAND) [110][104]. A total of 2,820 individuals comprising of 1,432
European and 1,388 African Americans were examined in our study. We assessed the
study subjects’ smoking behavior using Fagerström test for nicotine dependence
(FTND) [121]. The nicotine dependence patients were defined as current smokers
with FTND score equal or greater than 4, and controls were defined as having FTND
score of 0 or 1 and have smoked at least 100 cigarettes in their lifetime (Table 4.1).

4.2.2 Targeted sequencing of FMO1 and FMO3

DNA samples were extracted from blood with Puragene. Targeted sequencings
on two 100kb regions of FMO1 and FMO3 were performed at the Center for Inherited
Disease Research (CIDR). These genomic regions also contain part of gene FMO4
and a whole psedogene FMO6P. The quality control was implemented in samples and
variants level respectively. The mean on-target coverage was 180x for each
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sequencing experiment and greater than 96% of on-target bases had a depth greater
than 20x.

4.2.4 Quality control measures

Data quality was systematically evaluated using a robust alignment and variant
calling workflow implemented by CIDR (http://www.cidr.jhmi.edu/index.html). Over
100 quality control metrics were evaluated in real time to quickly identify potential
errors and implement fixes throughout the sequencing process. Briefly, sample quality
controls were conducted based on batch effects, discordance with array data, alternate
callsets, relatedness and some research specific criteria. Strategies used for variant
quality control includes VQSR, duplicate sample discordance, Mendelian errors,
Hardy-Weinberg equilibrium (HWE), sequence context, locus report by gene and
genotype missing rate. All variants passed the Variant Quality Score Recalibration
with a mean quality score of 99, mean depth of 122 with no missing calls, no
Mendelian errors and zero discordances between duplicate samples. Importantly, all
the rare variants were then manually evaluated by the Quality Assurance/Quality
Control analysis team.

4.2.3 Statistical methods and bioinformatics analysis

A total of 1,432 European and 1,388 African Americans with targeted
sequencing of FMO1 and FMO3 were examined. General data analyses were
performed by R (R i386 3.2.1) [122]. To quantify the potential population
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stratification, we conducted principal component analysis (PCA) in the combined
sample (115,338 markers), as well as separately in the European American sample
(154,049 markers) and African American sample (218,399 markers), using a previous
collected genome-wide array dataset containing 950,847 SNPs [123]. Sequencing data
were annotated by sequencing data annotation software ANNOVAR [46]. After
variant level quality control, 5,105, 2,600 and 3,817 variants located within the two
targeted genomic regions (FMO1/FMO3) were extracted from combined, European
and African American sample set, respectively.

Variants satisfying the following criteria were utilized in variant level analysis:
1) variants with MAF > 0.05 and 2) located within targeted gene regions or the
linkage disequilibrium (LD) blocks that are (partly) overlapped with the targeted gene
regions (detailed definition of blocks is given below). The association analysis was
conducted by fitting logistic regression model. The genotypic data were coded in
additive model. This analysis was performed in combined, European American, and
African American individuals separately (for combined subjects, we tested a union of
SNPs sets selected based on European and African American subjects). Gender and
age were included as covariates in all the three analyses. The first two principal
components based on the three sample sets were also utilized as covariates accounting
for the potential population stratification when fitting the logistic models. To address
the multiple comparison problem, we implemented Bonferroni correction. The
number of tests was calculated in the following way:
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（4.1）,

where for each dataset, n1 stands for the number of LD blocks generated by
this dataset and n2 is the number of variants that do not belong to any LD blocks. In
addition to testing associations for single variants, we also conducted haplotype based
analysis with combination of multiple variants in European and African American
datasets, respectively. LD blocks were constructed using the default algorithm taken
from Gabriel et al [124]. 95% confidence bounds on D’ are generated and each
comparison is called "strong LD" when the confidence bounds have upper bound ≥
0.98 and lower bound ≥ 0.7, and a block is created if 95% of informative comparisons
are "strong LD". Variant level association analysis and LD construction and haplotype
analyses were conducted using Plink [76].

Variants then were classified into two categories for the gene level analysis
(mostly rare variants). The two categories are: 1) gene-region variants set, that is the
variants located within the gene region, and 2) functional-region variants (variants
located within regions with significant functional significance, including exonic
regions, 3’/5’ UTR, smaller comparing to gene-region set).

For these two variants

sets, analysis was performed on variants with MAF less than 0.01, and 0.05. Both
SKAT and weighted burden test [125] were utilized for the gene level analysis. Same
as the variant level analysis, we also conducted this analysis in combined, European
and African American individuals separately. Gender, age and first two PCs based on
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the three sample sets were also included as covariates. LocusZoom was utilized to
make regional association plots [126].

We examined the targeted SNPs and/or genes using several bioinformatics
tools and databases. We utilized the protein-protein interaction database STRING
(http://string-db.org/) [127] to explore the potential interactions of our targeted genes.
The Regulome DB (http://regulomedb.org/) [128] was used to predict the potential
functional consequences the identified risk SNPs. This database is a web based
bioinformatics tool integrated with multiple types of data (including ChIP-seq,
DNase-seq, and eQTLs etc.) from the Encyclopedia of DNA Elements (ENCODE)
project[129].

4.3 Results
4.3.1 Variant-wise association of FMO genes and nicotine dependence

270, 326 and 368 variants were selected for variant-wise association analysis
in European, African American and combined sample set, respectively. 6 and 18
(covered 262 SNPs) LD blocks were constructed in European and African American
sample sets, respectively. Based on these LD blocks patterns, we obtained the
significant thresholds for variant-wise analysis were 3.6×10-3, 1.25×10-3 in European
American and African American sample set, respectively. We chose the most
conservative one as our P value threshold in analysis (1.25×10-3). Multiple different
significant variants were identified in European and African American datasets (Table
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4.2, Figure 4.1). A cluster of significant variants were identified in European
American individuals (with most significant SNP rs6674596, P=0.0004, OR=0.67,
FMO1). In African American individuals, we identified several clustered significant
variants (with the most significant SNP rs6608453, P=0.001) in pseudo gene FMO6P.

4.3.2 Haplotype based and gene-wise association of FMO genes and nicotine
dependence

We performed haplotype based analyses in European and African American
dataset separately. The P value thresholds were decided by Bonferroni correction and
thus were different for each dataset. We utilized 0.008(0.05/6) and 0.0025 (0.05/20)
as P value threshold for European and African American dataset, respectively. No
significant signals were identified through haplotype based analyses. Gene-wise
association analyses mainly focused on rare and/or low frequency variants in our
dataset. Although we have tried multiple analytical schema (combination of different
MAF threshold and region definitions), no significant association signals were found
in this analysis (Table 4.3).

4.3.3 Bioinformatics analysis

Proteins that show evidence for interaction with proteins encoded by FMO1,
FMO3 and FMO6P were extracted from STRING (Figure 4.2-4.4). Both FMO1 and
FMO3 have a strong relation with a variety of genes belong to CYP gene families.
FMO6P, however, as a pseudo gene, only showed limited evidence related with
PRSS16. We explored the top significant variants (rs6674596 and rs608453) in
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Regulome DB to investigate their potential biological significance. Regulome DB has
its own scoring system to measure the biological significance of a variant. The range
of the scores is from 1-6, and the smaller the score is, the more evidence that indicate
this variant has biological significance. Rs6674596 has a Regulome DB score of 5,
and it located within a DNase hypersensitive area of assayed in multiple cell types. In
addition, this variant also located at a sequence motif region (HNF1). Rs608453 has a
Regulome DB score of 6. It also located in the a sequence motif (Cdx). No expression
quantitative trait loci (eQTL) or transcription factor (TF) binding related evidence
were shown for neither variants.

4.4 Discussion
As part of a large scale targeted sequencing study focusing on
nicotine-dependent/nondependent smokers, our aim was to test the hypothesis that
genetic polymorphisms of flavin-containing monooxygenase genes contribute to the
risk of nicotine dependence. The underlying rationale of this study is based on the fact
that flavin-containing monooxygenase genes are key genes of the nicotine metabolism
pathway [118]. FMO1 may play a role in nicotine metabolism and contributed to the
nicotine level in brain organ [130], and FMO3 encodes flavin-containing
monooxygenase 3 (encoded by FMO3), which can metabolize a small percentage of
nicotine into nicotine N’-oxide [118]. We studied both rare and common variants in
FMO1, FMO3 and FMO6P through large scale targeted sequencing.
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A number of common variants in FMO1 were identified to be significantly
associated with nicotine dependence, and we noted that there was an ethnic-specific
pattern. We identified a cluster of significant variants in FMO1 in the European
Americans. The most significant variant was rs6674596 (P=0.0004, OR=0.67,
MAF_EA=0.135, MAF_AA=0.463). However, this significant result was not
replicated in our African American dataset (P=0.9325, OR=1.01). The association
signals for FMO1 have been reported by Hinrichs et al [120]. Several significant
SNPs reported in that paper, including rs742350 and rs1126692, were also identified
to be significant in our study. Considering both studies utilized COGEN samples, our
results on the common SNPs basically replicated Hinrichs’ results. In addition to the
significant findings in European American sample set, we also identified a set of
significant variants located on gene FMO6P from the African American dataset (with
the most significant SNP rs6608453, P=0.001, MAF_AA=0.097, MAF_EA=0.192).
Just like significant variants were only identified in European Americans, this
significant signal of FMO6P was only identified in African Americans but failed to be
replicated in European Americans (P= 0.1109, OR=1.17). No significant SNPs were
identified from the combined sample set, although in the combined samples set the
sample size almost doubled with a correspondent increment in statistical power. The
reasons behind this ethnic-specific pattern might be complex, and the most plausible
one is differences in the regional LD structure between the two racial/ethnic groups.
This difference might mean the surrogate SNPs miss the signal created by the real
underlying susceptible variants in a specific set of samples.
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One major advantage of our targeted sequencing study is that we can examine
every possible DNA variations in our targeted regions and conducted association
analysis thoroughly. However, in this study, we did not detect significant association
between the rare variants and nicotine dependence, although we systematically tried
many combinations of statistical methods, MAFs, region definitions and sample sets.
The most significant rare variant set was identified for gene FMO1 with region
definition of ―gene region‖ and MAF<0.01 in African Americans (P=0.0636). The
lack of significant findings for rare variants suggests that the significant associations
for common SNPs are not simply surrogates for rare variant associations (synthetic
associations) [131].

We found it interesting to examine the functional significance of the
significant common SNPs we identified. All of the significant common SNPs are
located either in introns or outside the gene. Therefore, if these significant common
SNPs alter function, it is not by changing protein structure. The most significant SNP
in FMO1, rs6674596, is located within a DNase hypersensitive area of assayed in
multiple cell types, and most of the regulatory regions and some promoter regions
tend to be DNase sensitive. This suggests that this SNP might have an effect on the
expression of gene FMO1. Nevertheless, without further evidence from biological
experiments, it is still too early to explain this association signal.

FMO6P is a pseudo gene which means that this gene cannot be properly
expressed as a protein, and it is probably because it is unable to produce a full length
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transcript [132]. FMO6P is reported to have significant sequence homology with
FMO3 [132]. Previous studies have set up direct links of SNPs in FMO6P with
chronic allograft dysfunction [133] and pharmacokinetic characteristics of sulindac
sulfide in premature labor [134]. One interesting note for these previous studies is that
the significant findings of FMO6P are always accompanied with significant findings
from FMO3, and at least in one study [135] , the significant SNP of FMO6P is in
complete LD with significant SNP of FMO3. This suggests that the significant hit in
FMO6P might be a surrogate for some true underlying signal in FMO3. However, in
our study, although some SNPs of FMO3 are indeed in complete LD with the
significant SNPs of FMO6P, the whole significant SNP cluster is located in the
FMO6P region (Figure 4.1). On the other hand, if the signal we identified in FMO6P
is not the surrogate for effects of SNPs in FMO3, but has an independent effect on
nicotine dependence, then further research will be needed to clarify the underlying
function of FMO6P.

A major strength of our study is that, unlike most of the common SNP based
association studies, is that we implemented a targeted sequencing technology for
genotyping of our study subjects. This enables us to consider both common and rare
variants within the three gene regions. Additionally, this study design enabled us to
analyze both SNVs and indels which are often omitted in SNP based study designs.
However, there are also some limitations to this study that need to be noted. Firstly,
we lack replication for our significant findings. The design using two racial/ethnic
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groups in our study enabled us to use as the two datasets as replication set for each
other. However, significant findings in the European American dataset were not
confirmed in the African American dataset. In addition, our sample size limited the
statistical power to detect potential modest effects of SNPs. This is a common
challenge, especially when using study designs, such as targeted sequencing, which
generate genotype data at many variants, leading to multiple comparisons and
corresponding stringent significance requirements. Future work to address this
challenge would be to combine multiple sequenced datasets using meta-analysis; such
approaches have been productive for GWAS of complex traits and have yet to be fully
leveraged for sequencing studies and rare variant analyses.

In summary, we tested the genetic effects of three flavin-containing
monooxygenases genes (FMO1, FMO3 and FMO6P) on nicotine dependence by
performing targeted sequencing on 2,852 nicotine-dependent and non-dependent
smokers. We performed both variant-level and gene/region-level analyses to examine
the genetic association of rare, low frequency and common variants within these
region and nicotine dependence, and both SNVs and indels. We identified significant
association signals for gene FMO1 and FMO6P. Replications of our finds in other
ethnic groups were needed in the future. Most of the significant variants identified
were SNPs located within intron regions or with unknown functional significance,
indicating a need for future work to understand the underlying functional significance
of these signals.
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4.5 Figures

Figure 4.1 Regional association plots of FMO1-FMO3-FMO6P genomic region based on European Americans and African Americans. a)
European Americans and b) African Americans. The blue dash lines are the –log10(P-value) threshold used in our study(1.25×10-3).
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Figure 4.2 Protein-protein interaction network of FMO1.
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Figure 4.3 Protein-protein interaction network of FMO3.
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Figure 4.4 Protein-protein interaction network of FMO6P.
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4.6 Tables
Table 4.1 Characteristics of study subjects
Nicotine dependent

Non-dependent

1,583

1,237

Female

901(59%)

805(65%)

Male

682(41%)

432(35%)

European American

730(46%)

702(57%)

African American

853(54%)

535(43%)

Age in year, mean (range)

37(25-45)

36(25-45)

FTND score*, mean (range)

6.34 (4-10)

0.16(0-1)

Sample, n

Gender

Ethnicity

*FTND is the Fagerström Test for Nicotine Dependence.
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Table 4.2 Significant signals in variant-wise association analysis.
CHR

VAR

GENE

POS

A1 OR_EA P_EA MAF_EA OR_AA P_AA MAF_AA

1

rs11812044

FMO6P 171115567 A

1.16

0.1232

0.19

0.65

0.0012

0.10

1

rs17565793

FMO6P 171116267 C

1.16

0.1232

0.19

0.65

0.0012

0.10

1

rs17623477

FMO6P 171116304 C

1.16

0.1232

0.19

0.65

0.0012

0.10

1

rs7051747

FMO6P 171116550 G

1.16

0.1232

0.19

0.65

0.0012

0.10

1

rs7066454

FMO6P 171116603 T

1.16

0.1232

0.19

0.65

0.0012

0.10

1

rs7063044

FMO6P 171116760 T

1.16

0.1232

0.19

0.65

0.0012

0.10

1

rs6608453

FMO6P 171117140 T

1.17

0.1109

0.19

0.64

0.0010

0.10

1

rs6608454

FMO6P 171117170 C

1.16

0.1232

0.19

0.65

0.0012

0.10

1

rs12726624

FMO1 171231630 G

0.67

0.0004

0.13

1.03

0.7385

0.47

1

rs17581251

FMO1 171232446 T

0.67

0.0011

0.12

0.98

0.8685

0.08

1 rs28360379_indel FMO1 171234851 A

0.68

0.0006

0.13

0.99

0.8698

0.43

1

rs6674596

FMO1 171235088 T

0.67

0.0004

0.14

1.01

0.9325

0.46

1

rs13376631

FMO1 171235742 G

0.69

0.0009

0.13

1.00

0.9831

0.43

1

rs12094878

FMO1 171243863 C

0.69

0.0012

0.14

1.04

0.6315

0.47

1

rs12062692

FMO1 171245579 G

0.69

0.0009

0.14

0.97

0.7002

0.48

1

rs7539057

FMO1 171248614 A

0.70

0.0012

0.14

0.95

0.4840

0.42

1

rs742350

FMO1 171250044 T

0.69

0.0012

0.14

1.03

0.6911

0.46

1

rs12091482

FMO1 171251509 T

0.70

0.0012

0.14

0.94

0.4723

0.42

1

rs10399952

FMO1 171251663 G

0.69

0.0011

0.14

0.95

0.5037

0.42

1

rs10399602

FMO1 171251876 C

0.70

0.0012

0.14

0.95

0.4840

0.42

1

rs7519999

FMO1 171251958 G

0.70

0.0012

0.14

0.95

0.4840

0.42

1

rs1126692

FMO1 171252287 G

0.70

0.0012

0.14

0.93

0.3914

0.46
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1

rs12092985

FMO1 171252537 A

0.70

0.0012

0.14

0.95

0.4840

0.42

1

rs10912714

FMO1 171253037 G

0.69

0.0011

0.14

0.95

0.4840

0.42

1

rs12059179

FMO1 171255346 T

0.70

0.0012

0.14

0.91

0.2620

0.39

Significant findings were highlighted in bold.
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Table 4.3 Full results of gene-wise association analysis.
Gene

Population

MAF

FMO1

European American <0.05

<0.01

African American <0.05

<0.01

Combined

<0.05

<0.01

FMO3

European American <0.05

<0.01

African American <0.05

<0.01

Combined

<0.05

Region

SKAT

Burden

gene region

0.8072

0.2071

functional region

0.8003

0.2857

gene region

0.5491

0.1463

functional region

0.8020

0.2657

gene region

0.2905

0.2146

functional region

0.8675

0.2844

gene region

0.0636

0.2481

functional region

0.9902

0.8136

gene region

0.2030

0.4330

functional region

0.4013

0.4399

gene region

0.5486

0.7550

functional region

0.7578

0.6936

gene region

0.4270

0.2791

functional region

0.9838

0.3735

gene region

0.8539

0.6863

functional region

0.8246

0.1389

gene region

0.7460

0.5758

functional region

0.3600

0.6912

gene region

0.9340

1.0000

functional region

0.5992

0.3285

gene region

0.1351

0.9251

functional region

0.8212

0.5602
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<0.01

FMO6P European American <0.05

<0.01

African American <0.05

<0.01

Combined

<0.05

<0.01

gene region

0.1902

0.0691

functional region

0.6783

0.4064

gene region

0.3707

0.3239

functional region

0.2326

0.1856

gene region

0.2917

1.0000

functional region

0.0948

0.3778

gene region

0.7999

0.3774

functional region

0.2711

0.6926

gene region

0.8139

0.3701

functional region

0.1175

0.6725

gene region

0.6998

0.7264

functional region

0.3588

0.5644

gene region

0.5938

0.1462

functional region

0.7372

0.5602
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Chapter 5: Evaluation and optimization
of multiple centrality measures in human
protein-protein interaction network
5.1 Introduction
Human gene networks are graphical representations of the interactions between
the genes. In a human gene network, genes are represented as nodes and the relationships
among them as edges. Human gene networks can be divided into three categories: 1)
Human gene networks derived from the curated knowledge; 2) Human gene networks
based on the experimental data of physical interactions, and 3) those that are inferred
from high-throughput data [136]. Centrality is a key indicator that identifies the most
important vertices within a graph. To quantify centrality, four major measurements have
been proposed: 1) Degree centrality, which simply counts the number of interactions to a
node; 2) Betweenness centrality, where nodes which fall in the shortest path of other
nodes have high betweenness; 3) Closeness centrality, which is related to the topology of
the nodes in a network; and 4) Eigenvector centrality which ranks the nodes in a network
based on its integrating neighbors [137]. Despite some early studies [138][139] that
utilize the simplest degree centrality measure, most of the recent research projects have
implemented the eigenvector centrality measure, such as algorithms modified from the
Google PageRank algorithm, to evaluate the importance of a gene in a gene network
[35][140]. However, research questions such as to what extent these centrality measures
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can represent the functional significance of genes or whether any of these centrality
measures outperformed others have never been seriously investigated.
In this chapter, we aim to investigate the followed three scientific questions: 1)
Can centrality reflect the biological significance of genes in a general human gene
network? 2) Among these four commonly used centrality measures, does any of them
outperform others? 3) Will they do better if we combine several centrality measures
together using machine learning algorithms? To answer these scientific questions, we
construct a comprehensive human gene-gene network using protein-protein interaction
(PPI) data.

5.2 Materials and Methods
5.2.1 Construction of human protein-protein interaction network
To evaluation the efficacy of multiple centrality measures as indicators of the
biological significance of genes, we first constructed a genome-scale human gene
network based on human protein-protein interaction (PPI) data. We extracted our PPI
data from the STRING database [127]. As a database of known and predicted
protein-protein interactions, STRING provides data users each protein-protein interaction
with a confidence score. To evaluate the potential effects of the quality of PPI data to our
study results, we constructed 4 human general dataset based on the full PPI dataset and
PPI dataset with top 75%, 50% and 25% high confidence score, respectively.
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5.2.2 Calculation of multiple centrality measures
Four measurements of centrality were calculated based on our general human
gene network, including degree centrality, betweenness centrality, closeness centrality
and pagerank centrality. Degree centrality is simply the number of adjacent edges to each
node. Betweenness centrality equals to the number of shortest paths from all vertices to
all others that pass through that node. Closeness centrality is defined as the reciprocal of
the farness which is the sum of distances of a node to all other nodes in a network.
Pagerank centrality ranks the nodes in a network based on its integrating neighbors. The
R package igraph was utilized to perform the construction of human network and the
calculations of these centrality measures [141].
5.2.3 Extraction of human essential gene sets
To evaluate the centrality measures as indicators of the functional significance of
human genes, besides the general human gene network we constructed, we also need a set
of genes to serve as ―true answers‖, which means that we are sure that these genes should
be biologically essential to human beings. We prepared our human essential gene sets in
the following three ways (resulting in four gene sets):
1) Online Gene Essentiality database (OGEE). OGEE is an online database that records
both experimentally tested essential and non-essential genes [142].Two categories of
essential genes, large-scale experiments based and text-mining based, were recorded
in the OGEE database. We extracted these two sets of essential human genes from
this database, and they were marked as OGEE.experiment and OGEE.textmining in
the following, respectively.
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2) Mendelian disorder related gene sets (marked as OMIM in the following). We
extracted a set of human genes that were reported to cause mendelian disorders from
Online Mendelian Inheritance in Man (OMIM) [143].Two files, the GeneMap file
and MorbidMap file, were provided by OMIM. GeneMap contains the information
that is centered by genes while MorbidMap file classified genes by their related
phenotypes. The Mendelian disorder related genes were not specifically indicated for
each term. To extract a potential gene list, we conducted the following filtering
strategy:
i. We removed those terms in both files that were tagged by ―[]‖, ―{}‖ or a question
mark ―(?)‖.Brackets, ―[]‖, indicate "nondiseases," mainly genetic variations that
lead to apparently abnormal laboratory test values but not disorders. Braces, ―{}‖,
indicate mutations that contribute to susceptibility to multifactorial disorders or to
susceptibility to infection. A question mark, ―?‖, before the disease name
indicates an unconfirmed or possibly spurious mapping.
ii. For the GeneMap file, we only selected those terms with an indicator ―C‖
(confirmed), which means this association was observed in at least two
laboratories or in several families.
iii. For MorbidMap, we only selected those terms with an indicator ―(3)‖, which
means the the molecular basis of the disorder is known.
iv. We then merged the two gene lists obtained from the GeneMap file and
MorbidMap file, and obtained the OMIM gene set.
3) Empirical gene sets (marked as ExAC in the following). This is an essential gene set
that is extracted based on the Exome Aggregation Consortium (ExAC) data.ExAC
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and includes exome sequencing data from a wide variety of large-scale sequencing
projects spanning 60,706 unrelated individuals[144]. We extracted a set of essential
genes by selecting genes that do not contain any destructive variants. The basic
rationale of this gene set is that if a gene is very important and essential for human
beings, disruptive mutations of this gene cannot be found in people with no severe
pediatric disease. We utilized ExAC data set to obtain this gene set in the following
filtering strategy:
i. A standard quality control (QC) process was applied to the ExAC dataset, only
variant calls with quality indicating as ―PASS‖ were included in the following
study.
ii. We removed those genes that contained frameshift indels in any of the 60,706
individuals and this step reduced the gene number to 4,465. Frameshift indels are
very disruptive mutations that may completely disable the gene function.
iii. We removed genes in major histocompatibility complex (MHC) regions. The
rationale of this step is that there are a lot of repetitive sequences in this region
and this severely affected the quality of the sequencing experiment. Therefore, the
genes we identified in MHC regions that contain no frameshift indels may not be
because that these genes are important, it may be just because of the low quality
of sequencing. We eliminated those variants with low quality during the QC
process. After applying this strategy, there are 2,760 genes left.
iv. We assumed the length of coding sequence (CDS) of a gene might affect the
chance that a frameshift mutation occurs within the gene. Therefore, we ranked
the 2,760 genes by their length of CDS and only included the 1,200 genes with
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shorter CDS.
The basic rationale behind the selection of essential gene sets is that we want to
collect a set of genes that are ―functionally significant‖ for human beings (so they can
serve as the ―true answer‖ in ROC analyses).

It is art more than science to select these

gene sets because there is no universal standard to determine what kind of genes can be
considered ―functionally significant‖. Lethality is the first potential criterion. However, it
is difficult to apply this standard directly due to ethical issues. To overcome this
difficulty, we utilized two methods. The first one is the experimental method. We can
obtain a set of genes that were experimentally proven to be lethal when knocked out in
model organisms, and then map those genes back to the human genome and extract the
homologous genes. This defines to the two gene sets we obtained from OGEE. Another
one is the observational method. We simply examine the genomes data of human
populations to examine whether there are any genes without disruptive mutations. This
defines the empirical gene set (ExAC). In addition to lethality, a list of causal genes of
mendelian disorder might be another choice for a set of functionally significant genes.
5.2.4 Comparisons and evaluations of different centrality measures
To compare the effecacy of these four measurements of centrality as predictors of
functional significance of genes in human gene network, we made receiver operating
characteristic (ROC) curves in the following ways:
1) We checked the four essential gene sets by each definition of centrality measure.
2) We checked the four different centrality measure for each essential gene set.
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5.2.5 Logistic regression model by combination of multiple centrality measures
To evaluate whether there is an improvement using a combined score of different
combinations of these centrality measures, we constructed a series of logistic regression
models. Due of the severe multicollinearity among these four degree centrality measures
(Figure 5.1), we fitted our model using a penalized regression technique. The 10-fold
cross-validation approach was used to assess the performance of these prediction models.
We calculated the area under curve (AUC) as a major indicator for comparisons of the
models. Regression model fitting and model comparisons were conducted by R package
glmnet [145].

5.3 Results
5.3.1 Human protein-protein interaction network and essential gene sets
We constructed a general human gene network that covered 18,199 human protein
coding genes using the full PPI data from STRING. This gene network covered 82.6% of
human genes. We obtained four essential gene sets, including OGEE.experiment (1,511),
OGEE.textmining (1,502), OMIM (1,244) and ExAC (1,200) gene set by the methods
described above. The number of genes for each gene set and the overlaps are shown in
Table 5.1. From this table, we can see that the four essential gene sets we extracted were
basically independent from each other with limited overlaps. The following main results
were conducted using human gene network constructed from the full PPI data
downloaded from STRING. Most of these results were validated in the other three
networks that were constructed with less but higher quality data (using 75%, 50% and 25%
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of the PPI data). We have summarized the information of these four networks in Table
5.2.
5.3.2 Comparisons of the four centrality measures as indicators of biological
significance
The centrality measures of the four essential gene sets were calculated based on
network constructed from full PPI data and shown in Figure 5.2. ANOVA analyses
indicated the differences in centrality of the five gene sets (four essential gene sets and
one random selected gene set) were significant in all of the four centrality measures (for
degree, closeness and pagerank centrality P<2×10-16; for betweenness centrality,
P=7.91×10-16).

In general, all of these four essential gene sets had higher centrality

compared to the randomly selected gene set for all four centrality measures. Two
essential gene sets that were extracted from OGEE (experiment and textmining) had
higher centralities compared to ExAC and OMIM gene sets. ROC curves that compared
the average centralities of these four essential gene sets were shown in Figure 5.3. The
centralities of the four essential gene sets were calculated based on network constructed
from 75%, 50% and 25% PPI data were shown in Figure 5.4- 5.6.
5.3.3 Comparison and optimization of the four centrality measures using logistic
model
The four centrality measures were compared using ROC curve for each essential
gene sets (Figure 5.7). As we can see from this figure that, for all these four essential
gene sets, there is no significant difference among the centrality measures. None of these
centrality measures outperformed the others as a predictor of the essentiality of genes in
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our general human gene network. This result was validated in human gene network
constructed using 25%, 50% and 75% PPI data, and these results were shown in Figure
5.8-5.10. The logistic models were evaluated using AUC measurements. The AUC plot
based on four essential gene sets were summarized in Figure 5.11. As we can see from
figure 3, in general, models including more centrality measures performed better (except
for OMIM gene set). However, this improvement was limited. The largest improvement
in AUC was around 0.05. Detailed information of AUC measures for different
combinations of centrality measures were summarized in Table 5.3.

5.4 Discussion
Previous genome-wide studies have shown that disrupted hub protein, protein that
locates at center position in a PPI network, is more likely to have lethal effect than a
non-hub protein, and this phenomenon is sometimes described as ―centrality-lethality rule‖
[146]. Our findings substantiated these previous observations. All of these four essential
gene sets had significantly higher centralities compared to a gene set randomly selected.
Another interesting observation is that the average centrality measures of these four
essential gene sets showed a gradient pattern. In general, essential gene sets extracted
from OGEE had highest average centrality, and OMIM gene set was slightly lower, while
ExAC gene set had the lowest average centrality. This pattern can be explained by the
differences of the potential functional significance among these essential gene sets.
OGEE gene sets were based on the experimental evidence of lethality in model
organisms, and the disruption of these genes might have lethal effects in human beings.
On the other hand, genes in OMIM gene set were causal genes of human mendelian
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disorders, and in most situations, disrupting these genes will cause mendelian disorders
but not to be lethal. In this sense, the OGEE gene sets should be more biologically
significant compared to genes in OMIM gene set. These evidence indicated that greater
biological significance implies average higher centrality in a general PPI network.
Another feature of our study that is different from previous research is that we provided a
tool to quantify and evaluate the efficacy of the centralities as predictors of functional
significance of genes in human gene network.
One thing interesting to note is the performance of ExAC gene set in our analyses.
The ExAC gene set was expected to have similar properties to the OGEE gene set
because both of them were based on the lethality standard as described in the method part.
However, the average centralities of ExAC gene set were the lowest among all of these
four gene sets. This might be due to two reasons. The first one is the ExAC gene set was
extracted based on around 60,706 individuals, and this sample size might not be large
enough to rule out some non-significant genes. In addition, several arbitrary criteria used
during the filtering process might increase the chance of the exclusion of some important
genes. For example, we utilized the length of coding sequence (CDS) as a filtering
criterion to reduce its potential effects. This criterion can rule out many small trivia genes,
however, as an arbitrary criterion, it might also exclude some potential functionally
significant genes.
The four centrality measures commonly used in network analysis constitute
different mathematical computations on the same underlying data. Degree centrality, for
example, is very easy to calculate, but betweenness and closeness centralities are
computational intensive especially when the adjacency matrix involved are big. Despite
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these differences in computational level, previous researchers have noticed the statistical
correlations among multiple centrality measures in a social network [147]. In our study,
we also observed a pattern of high correlation among the four centrality measures using
our general human gene network. In addition, this correlation property might also
contribute to the similarity of the performance of these centralities serving as predictors
as functional significance of genes. This high correlation property might also be the
reason that combinations of these centrality measures could only make a very limited
improvement for the performance of the logistic models. This indicates that the
development of multiple measures may be somewhat redundant, and they might perform
similarly in statistical analyses.
In this study, we have showed that genes with high centralities were enriched with
essential genes. A potential limitation of this study is that we only explored the property
of gene centrality in a general human gene network which covered most of the human
protein coding genes. The biological mechanisms are very complex and a general human
network cannot provide enough resolution to scrutinize detailed aspects of the enrichment
pattern of functional genes. Furthermore, in this study, we only investigated the gene sets
that are essential to human beings, and it might be more interesting to examine the
centrality property of genes that are susceptible to complex disorders/traits. Therefore, for
future study, it might be more fruitful for researchers to construct some functional
specific sub-networks and focused on susceptible genes of complex disorders/traits.
To conclude, in this study we have showed that there is a connection between the
essentiality and centrality of human genes. A pattern of strong correlations was identified
among the four commonly used centrality measures for a general human PPI network and
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the performance of each centrality measure was similar to others serving as predictors of
the essentiality of genes. The improvement of the prediction models was limited when
combined several different centrality measures.
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5.5 Figures

Figure 5.1 Scatter matrix for the four measurements of centrality. The outlier in this plot
is gene ubiquitin C(UBC). It was removed in the following model fitting.
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Figure 5.2 Comparison of the average centralities of the four essential gene sets. a)
degree centrality. b) closeness centrality. c) betweenness centrality. d) pagerank centrality.
A gene set tagged as ―Random‖ was also included for the comparison. This gene set
(with 850 genes) was randomly selected and was exclusive from the other four gene sets.
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Figure 5.3 ROC curves of the average centralities aomng the four essential gene sets. a)
degree centrality. b) closeness centrality. c) betweenness centrality. d) pagerank centrality.
The X and Y axis are false positive rate (FPR) and true positive rate (TPR), respectively.
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Figure 5.4 Comparison of the average centralities of the four essential gene sets using
network constructed by 25% PPI data. a) degree centrality. b) closeness centrality. c)
betweenness centrality. d) pagerank centrality. A gene set tagged as ―Random‖ was also
included for the comparison. This gene set (with 850 genes) was randomly selected and
was exclusive from the other four gene sets.
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Figure 5.5 Comparison of the average centralities of the four essential gene sets using
network constructed by 50% PPI data. a) degree centrality. b) closeness centrality. c)
betweenness centrality. d) pagerank centrality. A gene set tagged as ―Random‖ was also
included for the comparison. This gene set (with 850 genes) was randomly selected and
was exclusive from the other four gene sets.
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Figure 5.6 Comparison of the average centralities of the four essential gene sets using
network constructed by 75% PPI data. a) degree centrality. b) closeness centrality. c)
betweenness centrality. d) pagerank centrality. A gene set tagged as ―Random‖ was also
included for the comparison. This gene set (with 850 genes) was randomly selected and
was exclusive from the other four gene sets.
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Figure 5.7 ROC curves for evaluating the four centrality measures as predictors of
essentiality in human gene network. a) OGEE.experiment. b) OGEE.textmining. c)
OMIM. d) ExAC.
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Figure 5.8 ROC curves for evaluating the four centrality measures as predictors of
essentiality in human gene network constructed by 25% high quality PPI data. a)
OGEE.experiment. b) OGEE.textmining. c) OMIM. d) ExAC.
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Figure 5.9 ROC curves for evaluating the four centrality measures as predictors of
essentiality in human gene network constructed by 50% high quality PPI data. a)
OGEE.experiment. b) OGEE.textmining. c) OMIM. d) ExAC.
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Figure 5.10 ROC curves for evaluating the four centrality measures as predictors of
essentiality in human gene network constructed by 75% high quality PPI data. a)
OGEE.experiment. b) OGEE.textmining. c) OMIM. d) ExAC.
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Figure 5.11 AUC plot based on four essential gene sets. a) OGEE.experiment. b)
OGEE.textmining. c) OMIM. d) ExAC. Numbers at the top of each plot indicated the
number of variables included in regression models. Only largest AUC measures were
shown in this plot for different variable combinations.
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5.6 Tables
Table 5.1 Number of genes in each essential gene sets and the pattern of overlaps.
OGEE.experiment (%) OGEE.textmining (%) OMIM (%) ExAC (%)

Covered by Network (%)

OGEE.experiment

1,511 (100)

298 (19.8)

170 (13.9)

150 (12.5)

1,441 (95.4)

OGEE.textmining

298 (19.7)

1,502 (100)

302 (24.7)

133 (11.1)

1,455 (96.9)

OMIM

170 (11.3)

302 (20.1)

1,224 (100)

110 (9.2)

1,191 (97.3)

ExAc

150 (9.9)

133 (8.9)

110 (9.0)

1,200 (100)

1,140 (95.0)
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Table 5.2 Summarized information of the four human gene network.
Combined Score threshold Number of genes covered (% to human genome)
Network 100

/

18199 (82.6)

Network 75

175

18173 (82.5)

Network 50

212

18146 (82.4)

Network 25

317

18076 (82.1)
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Table 5.3 Detail information of AUC measures for different models
Models

OGEE.experiment OGEE.textmining

OMIM

ExAc

degree (1)

0.7345

0.7409

0.6703

0.5958

closeness (2)

0.7461

0.7483

0.6856

0.6131

betweenness (3)

0.6953

0.7280

0.5569

0.5324

pagerank (4)

0.7323

0.7440

0.6763

0.5976

(1)+(2)

0.7456

0.7479

0.6841

0.6135

(1)+(3)

0.7337

0.7400

0.6682

0.6001

(1)+(4)

0.7353

0.7637

0.7010

0.5971

(2)+(3)

0.7459

0.5514

0.6836

0.6131

(2)+(4)

0.7322

0.7492

0.6812

0.6133

(3)+(4)

0.7460

0.7432

0.6720

0.5986

(1)+(2)+(3)

0.7456

0.7489

0.6848

0.6122

(1)+(2)+(4)

0.7457

0.7859

0.7154

0.6109

(1)+(3)+(4)

0.7296

0.5390

0.7043

0.5986

(2)+(3)+(4)

0.7459

0.7496

0.6805

0.6122

(1)+(2)+(3)+(4)

0.7484

0.7882

0.7250

0.6115
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Chapter 6: Centrality pattern of
susceptibility genes to complex disorders
in functional specific protein-protein
interaction sub-networks
6.1 Introduction
The biological processes in humans are regulated through complex molecular
networks. One of the most important features of such networks is that the effect caused
by blocking one pathway within a network can be bypassed through some other ―back
door pathways‖. Accordingly, if a gene loses its function because of mutation, and if it is
not located at the central position of a gene network, it may have little impact to the
biological process due to the bypassing effects. On the other hand, if this gene has a
relatively high centrality in the gene network, the loss of its function may block several
pathways simultaneously and therefore no bypassing pathway can be used to supplement
its loss of function. In chapter five, we have shown the centrality distribution of several
essential gene sets in a general human gene network. In this chapter, we will present what
the centrality distribution pattern would be in function specific sub-networks for several
sets of susceptibility genes contributing to complex disorders.
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6.2 Methods and Materials
6.2.1 Construction of human PPI network and calculation of centrality
We utilized known and predicted PPI data from STRING (http://string-db.org/) to
construct our human PPI network [127]. Besides the human PPI network constructed
using the full dataset from STRING, we also utilized the quality score provided by
STRING to construct human PPI network with only 50% of the STRING data with
higher quality score to validate the results we obtained from the network constructed
using full PPI data. Centrality of genes was measured by degree centrality [148]. R
package igraph was utilized for network construction and related analyses [141].

6.2.2 Construction of brain function related sub-networks
RNA-sequence data from the database The Human Protein Atlas
(http://www.proteinatlas.org/) were utilized to construct brain function related
sub-networks [149]. The number of Fragments Per Kilobase gene model and Million
reads (PKFM) values of cerebral cortex were utilized as a filter criterion, and a series of
brain function related sub-networks were constructed based on genes that have a PKFM
value in cerebral cortex greater than a certain threshold. We labeled the human general
PPI network as network No.0. Then, genes that have a PKFM value in cerebral cortex
greater than 0.1×average PKFM in all human tissues (data of 44 tissues were recorded in
the database) were extracted and constructed as sub-network No. 1. Genes that have a
PKFM value in cerebral cortex greater than 0.2×average PKFM in all human tissues were
extracted and constructed as sub-network No. 2, and so on so forth. 30 sub-networks
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were constructed, and the sub-networks with the larger number have fewer genes but
these genes were more related with brain activity.
6.2.3 Extraction of susceptibility genes to complex disorders
Susceptibility genes of 25 complex disorders were extracted from the GWAS
catalogue (http://www.ebi.ac.uk/gwas/) [7]. Reported genes were extracted from the
GWAS catalogue for each disorder. These 25 complex disorders can be classified into
seven classes including neurodegenerative disorders, psychiatric disorders, liver related
disorders, skin related disorders, kidney related disorders, pancreas related disorders and
lung related disorders, and the last five classes can be combined as non-brain related
disorders (Table 6.1). Additionally, an essential gene set was also extracted from online
gene essentiality database (OGEE, http://ogeedb.embl.de/) as a comparison set. This
essential gene set was collected based on large scale experiments on model organisms
with lethality as an important criterion for recruiting them. To control potential
confounding factors, some disorders that were difficult to be defined as brain or
non-brain related disorders (such as obesity and substance addiction) were not included in
this study. In addition, this study mainly focused on complex disorders as a qualitative
variable, genes that only affect quantitative medical indicators of the disorders were not
included.

6.2.4 Statistical analyses
Two levels of enrichment pattern of susceptibility genes to complex disorders
were analyzed and compared among all these three major categories of complex disorders.
The first level is on the number of genes and the second level is the average/median
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centrality of genes. We utilized a 1,000 permutation technique to compare these
enrichment patterns of the three complex disorder categories in a series of brain function
related sub-networks. For the centrality level, null distribution of the average/median
centrality for each gene set was created through permutation in each sub-networks and
the general human network. Then the P values of the observed average/median centrality
of each gene set were calculated.

6.3 Results
6.3.1 Construction of general human networks and brain function related
sub-networks
A total of 31 human PPI gene networks were constructed (1 general network and
30 brain function related sub-networks). Summarized information of these gene networks
are shown in Table 6.2. The largest network, network No. 0 is a general human PPI gene
network with 18,041 genes. The smallest sub-networks, network No. 30, is constructed
by genes that were 3 times expressed in cerebral cortex comparing to the average level. It
only included 1,774 genes but these genes were highly expressed in brain and are highly
related to brain activity.
6.3.2 Extraction of susceptibility genes to complex disorders and their centrality in
multiple networks
A total of 468, 724 and 814 genes were extracted for neurodegenerative disorders,
psychiatric disorders and non-brain related disorders (Table 6.3). In addition to these
three gene sets, an essential gene set of 1,511 genes was also selected. The overlaps of
genes among these three complex disorder categories were very limited. There are only
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44 genes overlapped between neurodegenerative disorder and psychiatric disorder (9.4%
and 6.1% of neurodegenerative disorder and psychiatric disorder, respectively). Most of
these genes were covered by the general human PPI network (86%-91%). The degree
centrality distribution of these three disorder categories for network 0, 6, 12, 18, 24 and
30 are shown in Figure 6.1. Severe positive skewness and multiple outliers were
identified for all of these 6 networks. In this situation, median seems to be a more suitable
parameter to characterize the distribution of centrality.

6.3.3 Enrichment pattern of susceptibility genes to complex disorders in brain
related sub-networks
The enrichment pattern of susceptibility genes to complex disorders in gene
number was shown in Figure 6.2. As we can see, the two susceptibility gene sets related
to brain showed significant differences from the permuted background, while the
susceptibility gene sets of non-brain related disorders did not showed significant
enrichment pattern. The enrichment in high centrality of these susceptibility genes were
shown in Figure 6.3. Apparently, the median centrality of gene sets susceptible to
neurodegenerative and psychiatric disorders become more and more significantly higher
in a series of brain function related sub-networks as the genes constructed in these
networks become more and more highly expressed in human brain. On the other hand,
the gene set chosen by susceptibly to non-brain related disorders failed to show this
pattern. Although it is significant in the general human network (network 0), it did not
become more significant in more functional specific sub-networks. We also checked this
using the average of degree centrality (Figure 6.4), and a similar pattern was obtained. To
examine the potential effects of PPI data quality to our results, we also conducted this
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analysis in a network constructed by 50% higher quality PPI data (Figure 6.5). The
results indicated that the effects of quality of PPI data were limited. The centrality and
gene number enrichment for each of these five non-brain related complex disorder classes
are shown in Figure 6.6-6.10. The significance identified in network 0 was only identified
in pancreas related susceptibility gene sets. The characteristics of average degree
centrality for multiple gene sets in different sub-networks were also shown in line plots
(Figure 6.11). The top 20 genes with higher degree centrality in sub-network 30 are
summarized in Table 6.4.

6.4 Discussion
Susceptibility genes for complex disorders were believed to be peripheral in
human gene networks, because for complex disorders there are multiple genes each with
smaller effects, so that each gene seems not that important [38]. Our findings have shown
that this may be true in a general human gene network, however, in functional specific
sub-networks, the genes that confer risk to a complex disorder might have significant
higher degree centrality. The following two features can be obtained through the
centrality distribution patterns identified through our analyses. Firstly, compared to the
essential genes with lethal effects in model organisms, the three complex disorder related
gene sets have a very peripheral distribution in general human networks and the series of
brain function related sub-networks. Secondly, for both neurodegenerative and
psychiatric disorders, their centralities become significantly higher in the brain function
related sub-networks. This trend becomes more and more apparent when we utilized
more extreme criteria (PKFM values) to define the sub-networks. On the other hand,
susceptibility genes to non-brain related disorders failed to show this pattern. These two
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features indicated that for a certain type of complex disorder, the centrality of the
susceptibility genes are significantly higher within properly defined sub-networks with
specific function. Currently, there were several network based association mapping
prioritization methods [138][139]. Our findings indicated that for these methods, the key
point is what sub-networks were chosen, but not the fancy algorithms to incorporate P
values with the network parameters. Because centrality of genes in a gene network only
becomes meaningful when functional specific sub-networks are properly defined.
Another point interesting to note is that gene BDNF is in the 20 gene list (second
largest degree centrality) with top centrality in network 30 (Table 6.4) but has not been
extracted as a psychiatric or neurodegenerative disorders related genes. BDNF and its
val66-to-met mutation have been reported to be associated with several psychiatric
disorders including schizophrenia and bipolar disorder [150][151][152].We rechecked the
GWAS catalogue records and found that this gene was not reported as a susceptible gene
for any psychiatric disorders to date. However, this finding may indicate that centrality
can be utilized as a promising parameter in prioritization of candidate genes conferring
risk to complex disorders.
Since all of the data we utilized in this study were obtained through publically
available databases, our study is partially confined by the completeness of current
aggregation of relevant data. The targeted disorders of our research should be some
complex disorders that have been intensively studied in the past, so that we can extract a
larger number of susceptibility genes conferring risk for those disorders. In addition,
these disorders should also be relatively more concentrated in a certain human organ or
tissues, so it will make it easier to define a sub-network to test them and reduce the
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potential interference effects. This condition rules out some intensively studied disorders,
such as obesity. The two kinds of brain related disorders fitted the two conditions. Both
psychiatric disorders and neurodegenerative disorders have been studied thoroughly in
the past decade in GWAS and many susceptibility genes for these disorders have been
reported. With data from the Protein Atlas, it is easy for us to define brain function
related sub-networks and this process is totally independent of the susceptibility gene sets
we extracted. Tissue specific gene expression data is one way to define sub-networks.
One of a major advantage is that the sub-network will be highly functional specific to
certain human organs or tissues. Several other public available database, including
KEGG and Gene Ontology can be utilized to define sub-networks in the future.
To sum up, in this study, we examined the distributions of centrality for
susceptibility gene sets to complex disorders in multiple human gene function specific
networks. We identified that susceptibility gene sets to complex disorder have significant
higher centralities in properly defined function specific sub-networks.
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6.5 Figures

Figure 6.1 Distribution of degree centrality for the three disorder categories in network 0, 6, 12, 18, 24 and 30.
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Figure 6.2 Number of genes of susceptible gene sets in multiple brain related sub-networks. 1000 permutation was performed to create
the null distribution.
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Figure 6.3 Median of degree centrality and their statistical significance for susceptible gene sets in multiple brain related sub-networks.
1000 permutation was performed to create the null distribution.
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Figure 6.4 Average of degree centrality and their statistical significance for susceptible gene sets in multiple brain related
sub-networks. 1000 permutation was performed to create the null distribution.
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Figure 6.5 Median of degree centrality and their statistical significance for susceptible gene sets in multiple brain related sub-networks
using 50% higher quality score PPI data. 1000 permutation was performed to create the null distribution.
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Figure 6.6 Gene number and centrality enrichment pattern for susceptibility genes to
kidney related disorders in multiple brain related sub-networks. 1000 permutation was
performed to create the null distribution.
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Figure 6.7 Gene number and centrality enrichment pattern for susceptibility genes to liver
related disorders in multiple brain related sub-networks. 1000 permutation was performed
to create the null distribution.
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Figure 6.8 Gene number and centrality enrichment pattern for susceptibility genes to lung
related disorders in multiple brain related sub-networks. 1000 permutation was performed
to create the null distribution.
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Figure 6.9 Gene number and centrality enrichment pattern for susceptibility genes to skin
related disorders in multiple brain related sub-networks. 1000 permutation was performed
to create the null distribution.
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Figure 6.10 Gene number and centrality enrichment pattern for susceptibility genes to
pancreas related disorders in multiple brain related sub-networks. 1000 permutation was
performed to create the null distribution.
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Figure 6.11 Line plots of the average degree centrality for susceptible genes in
sub-network 0, 6, 12, 18, 24 and 30. A random gene set of 1,000 genes was selected
serving as control. a. full plot; b. plot without essential gene set. 95% CI of the mean
were added in the plot as the error bars.
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6.6 Tables
Table 6.1 Complex disorders selected for this research project.
Disorder category

Disorders

Neurodegenerative disorder Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease, Dementia, Eplipcy
Schizophrenia, bipolar disorder, major depression, autisms, Attention Deficit Hyperactivity Disorder
Psychiatric disorder

(ADHD)

Liver related disorder*

Hapetitis, Non-alcoholic fatty liver disease, Primary biliary cirrhosis, liver carcinoma

Skin related disorder*

Psoriasis, Melanoma, Acne, Non-melanoma skin cancer

Kidney related disorder*

Chronic kidney disease (CDK)

Pancreas related disorder* Type I&II diabetes
Lung related disorder*

Lung cancer, Chronic obstructive pulmonary disease (COPD), Asthma

*Non-brain related disorders
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Table 6.2 FPKM thresholds and number of genes covered for the 31 networks
constructed using STRING PPI data.
Networks
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30

*FPKM
threshold
>0.1
>0.2
>0.3
>0.4
>0.5
>0.6
>0.7
>0.8
>0.9
>1.0
>1.1
>1.2
>1.3
>1.4
>1.5
>1.6
>1.7
>1.8
>1.9
>2.0
>2.1
>2.2
>2.3
>2.4
>2.5
>2.6
>2.7
>2.8
>2.9
>3.0

No.gene **No.covered.gene (%)
19589
14552
13740
12900
12075
11215
10298
9325
8322
7316
6397
5637
5005
4508
4091
3741
3458
3226
3048
2860
2707
2564
2464
2351
2269
2185
2123
2053
1996
1941
1879

18041 (92.1)
13748 (94.5)
12973 (94.4)
12174 (94.3)
11401 (94.4)
10602 (94.5)
9742 (94.6)
8810 (94.5)
7856 (94.4)
6901(94.3)
6034 (94.3)
5301 (94.0)
4702 (93.9)
4241 (94.1)
3848 (94.1)
3517 (94.0)
3255 (94.1)
3038 (94.2)
2870 (94.2)
2694 (94.2)
2547 (94.1)
2412 (94.1)
2317 (94.0)
2212 (94.1)
2138 (94.2)
2059 (94.2)
2002 (94.3)
1937 (94.4)
1885 (94.4)
1833 (94.4)
1774 (94.4)

* PKFM threshold is defined as number × average PKFM in all tissues.
** Genes covered by STRING data.
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Table 6.3 Information of gene numbers of the three major susceptibility genes categories
Covered by general PPI network
Neuro (%)

Psych (%)

Non-brain (%) (%)

Neuro

468 (100)

44 (9.4)

36 (7.7)

419 (89.5)

Psych

44 (6.1)

724 (100)

39 (5.4)

660 (91.2)

39 (4.8)

814 (100)

700 (86.0)

Non-brain 36 (4.4)

Neurodegenerative disorders, psychiatric disorders and non-brain related disorders were
indicated as Neuro, Psych and Non-brain, respectively.
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Table 6.4 Top 20 genes with higher degree centrality in sub-network 30.
Gene
Ensembl ID
CHR Degree Centrality Disorders
CDK5 ENSG00000164885 7
710
BDNF ENSG00000176697 11
664
FYN ENSG00000010810 6
634
Neuro
MAPK11 ENSG00000185386 22
590
DIRAS2 ENSG00000165023 9
538
PPP3CA ENSG00000138814 4
536
SNCA ENSG00000145335 4
526
Neuro
RND1 ENSG00000172602 12
524
Psych
RIT2 ENSG00000152214 18
512
Neuro
RAP2A ENSG00000125249 13
506
RND2 ENSG00000108830 17
504
DLG2 ENSG00000150672 11
504
Neuro
PRKCA ENSG00000154229 17
502
MAPK4 ENSG00000141639 18
496
PRKACB ENSG00000142875 1
490
SST ENSG00000157005 3
488
GAD1 ENSG00000128683 2
478
GRIN2A ENSG00000183454 16
472
Psych
YWHAH ENSG00000128245 22
464
DIRAS1 ENSG00000176490 19
462
-

Band
q36.1
p14.1
q21
q13.33
q22.2
q24
q22.1
q13.12
q12.3
q32.1
q21.31
q14.1
q24.2
q21.1
p31.1
q27.3
q31.1
p13.2
q12.3
p13.3

Description
cyclin-dependent kinase 5
brain-derived neurotrophic factor
FYN proto-oncogene, Src family tyrosine kinase
mitogen-activated protein kinase 11
DIRAS family, GTP-binding RAS-like 2
protein phosphatase 3, catalytic subunit, alpha isozyme
synuclein alpha
Rho family GTPase 1
Ras-like without CAAX 2
RAP2A, member of RAS oncogene family
Rho family GTPase 2
discs, large homolog 2 (Drosophila)
protein kinase C, alpha
mitogen-activated protein kinase 4
protein kinase, cAMP-dependent, beta catalytic subunit
somatostatin
glutamate decarboxylase 1
glutamate receptor, ionotropic, N-methyl D-aspartate 2A
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein
DIRAS family, GTP-binding RAS-like 1
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